

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/31, C07K 14/35, 19/00, C12P 21/02, A61K 39/04</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 99/51748</b> <b>(43) International Publication Date:</b> 14 October 1999 (14.10.99)
<b>(21) International Application Number:</b> PCT/US99/07717 <b>(22) International Filing Date:</b> 7 April 1999 (07.04.99)  <b>(30) Priority Data:</b> 09/056,556                      7 April 1998 (07.04.98)                      US 09/223,040                      30 December 1998 (30.12.98)                      US  <b>(71) Applicant:</b> CORIXA CORPORATION [US/US]; 1124 Columbia Street, Seattle, WA 98104 (US).  <b>(72) Inventors:</b> SKEIKY, Yasir, A., W.; 8327 - 25th Avenue N.W., Seattle, WA 98117 (US). ALDERSON, Mark; 1116 Grow Avenue Northwest, Bainbridge Island, WA 98116 (US). CAMPOS-NETO, Antonio; 9308 Midship Court Northeast, Bainbridge Island, WA 98110 (US).  <b>(74) Agents:</b> CORUZZI, Laura, A. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).		<b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> FUSION PROTEINS OF <i>MYCOBACTERIUM TUBERCULOSIS</i> ANTIGENS AND THEIR USES		
<b>(57) Abstract</b>  The present invention relates to fusion proteins containing at least two <i>Mycobacterium tuberculosis</i> antigens. In particular, it relates to bi-fusion proteins which contain two individual <i>M. tuberculosis</i> antigens, tri-fusion proteins which contain three <i>M. tuberculosis</i> antigens, tetra-fusion proteins which contain four <i>M. tuberculosis</i> antigens, and penta-fusion proteins which contain five <i>M. tuberculosis</i> antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**FUSION PROTEINS OF MYCOBACTERIUM  
TUBERCULOSIS ANTIGENS AND THEIR USES**

---

5    1.    **INTRODUCTION**

The present invention relates to fusion proteins containing at least two *Mycobacterium tuberculosis* antigens. In particular, it relates to bi- fusion proteins which contain two individual *M. tuberculosis* antigens, tri- fusion proteins which contain three *M.*  
10 *tuberculosis* antigens, tetra-fusion proteins which contain four *M. tuberculosis* antigens, and penta-fusion proteins which contain five *M. tuberculosis* antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

15    2.    **BACKGROUND OF THE INVENTION**

Tuberculosis is a chronic infectious disease caused by infection with *M. tuberculosis*. It is a major disease in developing countries, as well as an increasing problem in developed areas of the world, with about 8 million new cases and 3 million deaths each year. Although the infection may be asymptomatic for a considerable period of time, the  
20 disease is most commonly manifested as an acute inflammation of the lungs, resulting in fever and a nonproductive cough. If untreated, serious complications and death typically result.

Although tuberculosis can generally be controlled using extended antibiotic therapy, such treatment is not sufficient to prevent the spread of the disease. Infected individuals  
25 may be asymptomatic, but contagious, for some time. In addition, although compliance with the treatment regimen is critical, patient behavior is difficult to monitor. Some patients do not complete the course of treatment, which can lead to ineffective treatment and the development of drug resistance.

In order to control the spread of tuberculosis, effective vaccination and accurate  
30 early diagnosis of the disease are of utmost importance. Currently, vaccination with live bacteria is the most efficient method for inducing protective immunity. The most common *Mycobacterium* employed for this purpose is *Bacillus Calmette-Guerin* (BCG), an avirulent strain of *M. bovis*. However, the safety and efficacy of BCG is a source of controversy and some countries, such as the United States, do not vaccinate the general public with this  
35 agent.

Diagnosis of tuberculosis is commonly achieved using a skin test, which involves intradermal exposure to tuberculin PPD (protein-purified derivative). Antigen-specific T cell responses result in measurable induration at the injection site by 48-72 hours after injection, which indicates exposure to Mycobacterial antigens. Sensitivity and specificity  
5 have, however, been a problem with this test, and individuals vaccinated with BCG cannot be distinguished from infected individuals.

While macrophages have been shown to act as the principal effectors of *M. tuberculosis* immunity, T cells are the predominant inducers of such immunity. The essential role of T cells in protection against *M. tuberculosis* infection is illustrated by the  
10 frequent occurrence of *M. tuberculosis* in Acquired Immunodeficiency Syndrome patients, due to the depletion of CD4<sup>+</sup> T cells associated with human immunodeficiency virus (HIV) infection. Mycobacterium-reactive CD4<sup>+</sup> T cells have been shown to be potent producers of gamma-interferon (IFN- $\gamma$ ), which, in turn, has been shown to trigger the anti-mycobacterial effects of macrophages in mice. While the role of IFN- $\gamma$  in humans is less clear, studies  
15 have shown that 1,25-dihydroxy-vitamin D3, either alone or in combination with IFN- $\gamma$  or tumor necrosis factor-alpha, activates human macrophages to inhibit *M. tuberculosis* infection. Furthermore, it is known that IFN- $\gamma$  stimulates human macrophages to make 1,25-dihydroxy-vitamin D3. Similarly, interleukin-12 (IL-12) has been shown to play a role in stimulating resistance to *M. tuberculosis* infection. For a review of the immunology of  
20 *M. tuberculosis* infection, see Chan and Kaufmann, 1994, *Tuberculosis: Pathogenesis, Protection and Control*, Bloom (ed.), ASM Press, Washington, DC.

Accordingly, there is a need for improved vaccines, and improved methods for diagnosis, preventing and treating tuberculosis.

### 25 3. SUMMARY OF THE INVENTION

The present invention relates to fusion proteins of *M. tuberculosis* antigens. In particular, it relates to fusion polypeptides that contain two or more *M. tuberculosis* antigens, polynucleotides encoding such polypeptides, methods of using the polypeptides  
30 and polynucleotides in the diagnosis, treatment and prevention of *M. tuberculosis* infection.

The present invention is based, in part, on the inventors' discovery that polynucleotides which contain two to five *M. tuberculosis* coding sequences produce recombinant fusion proteins that retain the immunogenicity and antigenicity of their individual components. The fusion proteins described herein induced both T cell and B cell  
35 responses, as measured by T cell proliferation, cytokine production, and antibody

production. Furthermore, a fusion protein was used as an immunogen with adjuvants *in vivo* to elicit both cell-mediated and humoral immunity to *M. tuberculosis*. Additionally, a fusion protein was made by a fusion construct and used in a vaccine formulation with an adjuvant to afford long-term protection in animals against the development of tuberculosis.

- 5 The fusion protein was a more effective immunogen than a mixture of its individual protein components.

In a specific embodiment of the invention, the isolated or purified *M. tuberculosis* polypeptides of the invention may be formulated as pharmaceutical compositions for administration into a subject in the prevention and/or treatment of *M. tuberculosis* infection.

- 10 The immunogenicity of the fusion protein may be enhanced by the inclusion of an adjuvant.

In another aspect of the invention, the isolated or purified polynucleotides are used to produce recombinant fusion polypeptide antigens *in vitro*. Alternatively, the polynucleotides may be administered directly into a subject as DNA vaccines to cause  
15 antigen expression in the subject, and the subsequent induction of an anti-*M. tuberculosis* immune response.

It is also an object of the invention that the polypeptides be used in *in vitro* assays for detecting humoral antibodies or cell-mediated immunity against *M. tuberculosis* for diagnosis of infection or monitor of disease progression. Additionally, the polypeptides  
20 may be used as an *in vivo* diagnostic agent in the form of an intradermal skin test. Alternatively, the polypeptides may be used as immunogens to generate anti-*M. tuberculosis* antibodies in a non-human animal. The antibodies can be used to detect the target antigens *in vivo* and *in vitro*.

25

#### 4. BRIEF DESCRIPTION OF THE DRAWINGS

- Figure 1A and 1B. The nucleotide sequence (SEQ ID NO:1) and amino acid  
sequence (SEQ ID NO:2) of tri-fusion protein Ra12-TbH9-  
30 Ra35 (designated Mtb32A).  
Figure 2 : The nucleotide sequence (SEQ ID NO:3) and amino acid  
sequence (SEQ ID NO:4) of tri-fusion protein Erd14-DPV-  
MTI (designated Mtb39A).  
Figure 3A - 3D: The nucleotide sequence (SEQ ID NO:5) and amino acid  
35 sequence (SEQ ID NO:6) of tri-fusion protein TbRa3-38kD-

- Tb38-1.
- Figure 4A - 4D: The nucleotide sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8) of bi-fusion protein TbH9-Tb38-1.
- 5 Figure 5A - 5J: The nucleotide sequence (SEQ ID NO:9) and amino acid sequence (SEQ ID NO:10) of tetra-fusion protein TbRa3-38kD-Tb38-1-DPEP (designated TbF-2).
- Figure 6A and 6B: The nucleotide sequence (SEQ ID NO:11) and amino acid sequence (SEQ ID NO:12) of penta-fusion protein Erd14-DPV-MTI-MSL-MTCC2 (designated Mtb88f).
- 10 Figure 7A and 7B: The nucleotide sequence (SEQ ID NO:13) and amino acid sequence (SEQ ID NO:14) of tetra-fusion protein Erd14-DPV-MTI-MSL (designated Mtb46f).
- Figure 8A and 8B: The nucleotide sequence (SEQ ID NO:15) and amino acid sequence (SEQ ID NO:16) of tetra-fusion protein DPV-MTI-MSL-MTCC2 (designated Mtb71f).
- 15 Figure 9A and 9B: The nucleotide sequence (SEQ ID NO:17) and amino acid sequence (SEQ ID NO:18) of tri-fusion protein DPV-MTI-MSL (designated Mtb31f).
- Figure 10A and 10B: The nucleotide sequence (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20) of tri-fusion protein TbH9-DPV-MTI (designated Mtb61f).
- 20 Figure 11A and 11B: The nucleotide sequence (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:22) of tri-fusion protein Erd14-DPV-MTI (designated Mtb36f).
- Figure 12A and 12B: The nucleotide sequence (SEQ ID NO:23) and amino acid sequence (SEQ ID NO:24) of bi-fusion protein TbH9-Ra35 (designated Mtb59f).
- 25 Figure 13A and 13B: The nucleotide sequence (SEQ ID NO:25) and amino acid sequence (SEQ ID NO:26) of bi-fusion protein Ra12-DPPD (designated Mtb24).
- 30 Figure 14A-14F: T cell proliferation responses of six PPD+ subjects when stimulated with two fusion proteins and their individual components.
- Figure 15A-15F: IFN- $\gamma$  production of six PPD+ subjects when stimulated with two fusion proteins and their individual components.
- 35

- Figure 16A-16F: T cell proliferation of mice immunized with a fusion protein or its individual components and an adjuvant.
- Figure 17: IFN- $\gamma$  production of mice immunized with a fusion protein or its individual components and an adjuvant.
- 5 Figure 18: IL-4 production of mice immunized with a fusion protein or its individual components and an adjuvant.
- Figure 19A-19F: Serum antibody concentrations of mice immunized with a fusion protein or its individual components and an adjuvant.
- 10 Figure 20A-20C: Survival of guinea pigs after aerosol challenge of *M. tuberculosis*. Fusion proteins, Mtb32A and Mtb39A, were formulated in adjuvant SBAS1c (20A), SBAS2 (20B) or SBAS7 (20C), and used as an immunogen in guinea pigs prior to challenge with bacteria. BCG is the positive control.
- 15 Figure 21A and 21B: Stimulation of proliferation and IFN- $\gamma$  production in TbH9-specific T cells by the fusion protein TbH9-Tb38-1.
- Figure 22A and 22B: Stimulation of proliferation and IFN- $\gamma$  production in Tb38-1-specific T cells by the fusion protein TbH9-Tb38-1.
- 20 Figure 23A and 23B: Stimulation of proliferation and IFN- $\gamma$  production in T cells previously shown to respond to both TbH-9 and Tb38-1 antigens by the fusion protein TbH9-Tb38-1.

## 5. DETAILED DESCRIPTION OF THE INVENTION

25 The present invention relates to antigens useful for the treatment and prevention of tuberculosis, polynucleotides encoding such antigens, and methods for their use. The antigens of the present invention are fusion polypeptides of *M. tuberculosis* antigens and variants thereof. More specifically, the antigens of the present invention comprise at least two polypeptides of *M. tuberculosis* that are fused into a larger fusion polypeptide molecule. The antigens of the present invention may further comprise other components  
30 designed to enhance the immunogenicity of the antigens or to improve these antigens in other aspects, for example, the isolation of these antigens through addition of a stretch of histidine residues at one end of the antigen.

### 5.1. M. TUBERCULOSIS SPECIFIC ANTIGENS

35 The antigens of the present invention are exemplified in Figures 1A through 13B,



including homologues and variants of those antigens. These antigens may be modified, for example, by adding linker peptide sequences as described below. These linker peptides may be inserted between one or more polypeptides which make up each of the fusion proteins presented in Figures 1A through 13B. Other antigens of the present invention are  
5 antigens described in Figures 1A through 13B which have been linked to a known antigen of *M. tuberculosis*, such as the previously described 38 kD (SEQ ID NO:27) antigen (Andersen and Hansen, 1989, Infect. Immun. 57:2481-2488; Genbank Accession No. M30046).

10

## 5.2. IMMUNOGENICITY ASSAYS

Antigens described herein, and immunogenic portions thereof, have the ability to induce an immunogenic response. More specifically, the antigens have the ability to induce proliferation and/or cytokine production (*i.e.*, interferon- $\gamma$  and/or interleukin-12 production)  
15 in T cells, NK cells, B cells and/or macrophages derived from an *M. tuberculosis*-immune individual. The selection of cell type for use in evaluating an immunogenic response to a antigen will depend on the desired response. For example, interleukin-12 production is most readily evaluated using preparations containing B cells and/or macrophages. An *M. tuberculosis*-immune individual is one who is considered to be resistant to the  
20 development of tuberculosis by virtue of having mounted an effective T cell response to *M. tuberculosis* (*i.e.*, substantially free of disease symptoms). Such individuals may be identified based on a strongly positive (*i.e.*, greater than about 10 mm diameter induration) intradermal skin test response to tuberculosis proteins (PPD) and an absence of any signs or symptoms of tuberculosis disease. T cells, NK cells, B cells and macrophages derived from  
25 *M. tuberculosis*-immune individuals may be prepared using methods known to those of ordinary skill in the art. For example, a preparation of PBMCs (*i.e.*, peripheral blood mononuclear cells) may be employed without further separation of component cells. PBMCs may generally be prepared, for example, using density centrifugation through "FICOLL" (Winthrop Laboratories, NY). T cells for use in the assays described herein may  
30 also be purified directly from PBMCs. Alternatively, an enriched T cell line reactive against mycobacterial proteins, or T cell clones reactive to individual mycobacterial proteins, may be employed. Such T cell clones may be generated by, for example, culturing PBMCs from *M. tuberculosis*-immune individuals with mycobacterial proteins for a period of 2-4 weeks. This allows expansion of only the mycobacterial protein-specific T cells,  
35 resulting in a line composed solely of such cells. These cells may then be cloned and tested

with individual proteins, using methods known to those of ordinary skill in the art, to more accurately define individual T cell specificity. In general, antigens that test positive in assays for proliferation and/or cytokine production (*i.e.*, interferon- $\gamma$  and/or interleukin-12 production) performed using T cells, NK cells, B cells and/or macrophages derived from an  
5 *M. tuberculosis*-immune individual are considered immunogenic. Such assays may be performed, for example, using the representative procedures described below. Immunogenic portions of such antigens may be identified using similar assays, and may be present within the polypeptides described herein.

The ability of a polypeptide (*e.g.*, an immunogenic antigen, or a portion or other  
10 variant thereof) to induce cell proliferation is evaluated by contacting the cells (*e.g.*, T cells and/or NK cells) with the polypeptide and measuring the proliferation of the cells. In general, the amount of polypeptide that is sufficient for evaluation of about  $10^5$  cells ranges from about 10 ng/mL to about 100  $\mu$ g/mL and preferably is about 10  $\mu$ g/mL. The incubation of polypeptide with cells is typically performed at 37°C for about six days.  
15 Following incubation with polypeptide, the cells are assayed for a proliferative response, which may be evaluated by methods known to those of ordinary skill in the art, such as exposing cells to a pulse of radiolabeled thymidine and measuring the incorporation of label into cellular DNA. In general, a polypeptide that results in at least a three fold increase in proliferation above background (*i.e.*, the proliferation observed for cells cultured without  
20 polypeptide) is considered to be able to induce proliferation.

The ability of a polypeptide to stimulate the production of interferon- $\gamma$  and/or interleukin-12 in cells may be evaluated by contacting the cells with the polypeptide and measuring the level of interferon- $\gamma$  or interleukin-12 produced by the cells. In general, the amount of polypeptide that is sufficient for the evaluation of about  $10^5$  cells ranges from  
25 about 10 ng/mL to about 100  $\mu$ g/mL and preferably is about 10  $\mu$ g/mL. The polypeptide may be, but need not be, immobilized on a solid support, such as a bead or a biodegradable microsphere, such as those described in U.S. Patent Nos. 4,897,268 and 5,075,109. The incubation of polypeptide with the cells is typically performed at 37°C for about six days. Following incubation with polypeptide, the cells are assayed for interferon- $\gamma$  and/or  
30 interleukin-12 (or one or more subunits thereof), which may be evaluated by methods known to those of ordinary skill in the art, such as an enzyme-linked immunosorbent assay (ELISA) or, in the case of IL-12 P70 subunit, a bioassay such as an assay measuring proliferation of T cells. In general, a polypeptide that results in the production of at least 50 pg of interferon- $\gamma$  per mL of cultured supernatant (containing  $10^4$ - $10^5$  T cells per mL) is  
35 considered able to stimulate the production of interferon- $\gamma$ . A polypeptide that stimulates

the production of at least 10 pg/mL of IL-12 P70 subunit, and/or at least 100 pg/mL of IL-12 P40 subunit, per  $10^5$  macrophages or B cells (or per  $3 \times 10^5$  PBMC) is considered able to stimulate the production of IL-12.

In general, immunogenic antigens are those antigens that stimulate proliferation and/or cytokine production (*i.e.*, interferon- $\gamma$  and/or interleukin-12 production) in T cells, NK cells, B cells and/or macrophages derived from at least about 25% of *M. tuberculosis*-immune individuals. Among these immunogenic antigens, polypeptides having superior therapeutic properties may be distinguished based on the magnitude of the responses in the above assays and based on the percentage of individuals for which a response is observed. In addition, antigens having superior therapeutic properties will not stimulate proliferation and/or cytokine production *in vitro* in cells derived from more than about 25% of individuals who are not *M. tuberculosis*-immune, thereby eliminating responses that are not specifically due to *M. tuberculosis*-responsive cells. Those antigens that induce a response in a high percentage of T cell, NK cell, B cell and/or macrophage preparations from *M. tuberculosis*-immune individuals (with a low incidence of responses in cell preparations from other individuals) have superior therapeutic properties.

Antigens with superior therapeutic properties may also be identified based on their ability to diminish the severity of *M. tuberculosis* infection in experimental animals, when administered as a vaccine. Suitable vaccine preparations for use on experimental animals are described in detail below. Efficacy may be determined based on the ability of the antigen to provide at least about a 50% reduction in bacterial numbers and/or at least about a 40% decrease in mortality following experimental infection. Suitable experimental animals include mice, guinea pigs and primates.

### 5.3. ISOLATION OF CODING SEQUENCES

The present invention also relates to nucleic acid molecules that encode fusion polypeptides of *M. tuberculosis*. In a specific embodiment by way of example in Section 6, *infra*, thirteen *M. tuberculosis* fusion coding sequences were constructed. In accordance with the invention, any nucleotide sequence which encodes the amino acid sequence of the fusion protein can be used to generate recombinant molecules which direct the expression of the coding sequence.

In order to clone full-length coding sequences or homologous variants to generate the fusion polynucleotides, labeled DNA probes designed from any portion of the nucleotide sequences or their complements disclosed herein may be used to screen a genomic or cDNA library made from various strains of *M. tuberculosis* to identify the

coding sequence of each individual component. Isolation of coding sequences may also be carried out by the polymerase chain reactions (PCR) using two degenerate oligonucleotide primer pools designed on the basis of the coding sequences disclosed herein.

The invention also relates to isolated or purified polynucleotides complementary to the nucleotide sequences of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25, and polynucleotides that selectively hybridize to such complementary sequences. In a preferred embodiment, a polynucleotide which hybridizes to the sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25 or its complementary sequence under conditions of low stringency and encodes a protein that retains the immunogenicity of the fusion proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 is provided. By way of example and not limitation, exemplary conditions of low stringency are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 h at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 40°C, and then washed for 1.5 h at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 h at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and re-exposed to film. Other conditions of low stringency which may be used are well known in the art (*e.g.*, as employed for cross-species hybridizations).

In another preferred embodiment, a polynucleotide which hybridizes to the coding sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25 or its complementary sequence under conditions of high stringency and encodes a protein that retains the immunogenicity of the fusion proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 is provided. By way of example and not limitation, exemplary conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/mL denatured salmon sperm DNA. Filters are hybridized for 48 h at 65°C in prehybridization mixture containing 100 µg/mL denatured salmon sperm DNA and 5-20 X 10<sup>6</sup> cpm of <sup>32</sup>P-labeled probe. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.01%

PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1X SSC at 50°C for 45 min before autoradiography. Other conditions of high stringency which may be used are well known in the art.

In yet another preferred embodiment, a polynucleotide which hybridizes to the coding sequence of SEQ ID NOS:1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23 and 25 or its complementary sequence under conditions of moderate stringency and encodes a protein that retains the immunogenicity of the fusion proteins of SEQ ID NOS:2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 and 26 is provided. Exemplary conditions of moderate stringency are as follows: Filters containing DNA are pretreated for 6 h at 55°C in a solution containing 6X SSC, 5X Denhart's solution, 0.5% SDS and 100 µg/mL denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X 10<sup>6</sup> cpm <sup>32</sup>P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 h at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1X SSC and 0.1% SDS. Filters are blotted dry and exposed for autoradiography. Other conditions of moderate stringency which may be used are well-known in the art. Washing of filters is done at 37°C for 1 h in a solution containing 2X SSC, 0.1% SDS.

#### 5.4. POLYPEPTIDES ENCODED BY THE CODING SEQUENCES

In accordance with the invention, a polynucleotide of the invention which encodes a fusion protein, fragments thereof, or functional equivalents thereof may be used to generate recombinant nucleic acid molecules that direct the expression of the fusion protein, fragments thereof, or functional equivalents thereof, in appropriate host cells. The fusion polypeptide products encoded by such polynucleotides may be altered by molecular manipulation of the coding sequence.

Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence, may be used in the practice of the invention for the expression of the fusion polypeptides. Such DNA sequences include those which are capable of hybridizing to the coding sequences or their complements disclosed herein under low, moderate or high stringency conditions described in Sections 5.3, *supra*.

Altered nucleotide sequences which may be used in accordance with the invention include deletions, additions or substitutions of different nucleotide residues resulting in a sequence that encodes the same or a functionally equivalent gene product. The gene product itself may contain deletions, additions or substitutions of amino acid residues, which result in a silent change thus producing a functionally equivalent antigenic epitope.

Such conservative amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine, histidine and arginine; amino acids with uncharged polar head groups having similar hydrophilicity values include the following: glycine, asparagine, glutamine, serine, threonine and tyrosine; and amino acids with nonpolar head groups include alanine, valine, isoleucine, leucine, phenylalanine, proline, methionine and tryptophan.

The nucleotide sequences of the invention may be engineered in order to alter the fusion protein coding sequence for a variety of ends, including but not limited to, alterations which modify processing and expression of the gene product. For example, mutations may be introduced using techniques which are well known in the art, e.g., site-directed mutagenesis, to insert new restriction sites, to alter glycosylation patterns, phosphorylation, etc.

In an alternate embodiment of the invention, the coding sequence of a fusion protein could be synthesized in whole or in part, using chemical methods well known in the art. See, e.g., Caruthers *et al.*, 1980, *Nuc. Acids Res. Symp. Ser.* 7:215-233; Crea and Horn, 180, *Nuc. Acids Res.* 9(10):2331; Matteucci and Caruthers, 1980, *Tetrahedron Letter* 21:719; and Chow and Kempe, 1981, *Nuc. Acids Res.* 9(12):2807-2817. Alternatively, the polypeptide itself could be produced using chemical methods to synthesize an amino acid sequence in whole or in part. For example, peptides can be synthesized by solid phase techniques, cleaved from the resin, and purified by preparative high performance liquid chromatography. (See Creighton, 1983, *Proteins Structures And Molecular Principles*, W.H. Freeman and Co., N.Y. pp. 50-60). The composition of the synthetic polypeptides may be confirmed by amino acid analysis or sequencing (e.g., the Edman degradation procedure; see Creighton, 1983, *Proteins, Structures and Molecular Principles*, W.H. Freeman and Co., N.Y., pp. 34-49).

Additionally, the coding sequence of a fusion protein can be mutated *in vitro* or *in vivo*, to create and/or destroy translation, initiation, and/or termination sequences, or to create variations in coding regions and/or form new restriction endonuclease sites or destroy preexisting ones, to facilitate further *in vitro* modification. Any technique for mutagenesis known in the art can be used, including but not limited to, chemical mutagenesis, *in vitro* site-directed mutagenesis (Hutchinson, C., *et al.*, 1978, *J. Biol. Chem* 253:6551), use of TAB® linkers (Pharmacia), and the like. It is important that the manipulations do not destroy immunogenicity of the fusion polypeptides.

In addition, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the sequence. Non-classical amino acids include, but are not limited to, the D-isomers of the common amino acids,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino  
5 hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids, C $\alpha$ -methyl amino acids, N $\alpha$ -methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

10 In a specific embodiment, the coding sequences of each antigen in the fusion protein are joined at their amino- or carboxy-terminus via a peptide bond in any order. Alternatively, a peptide linker sequence may be employed to separate the individual polypeptides that make-up a fusion polypeptide by a distance sufficient to ensure that each polypeptide folds into a secondary and tertiary structure that maximizes its antigenic  
15 effectiveness for preventing and treating tuberculosis. Such a peptide linker sequence is incorporated into the fusion protein using standard techniques well known in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the first and second polypeptides;  
20 and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. Preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea *et al.*, Gene 40:39-46, 1985; Murphy *et al.*, Proc. Natl. Acad. Sci. USA  
25 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. The linker sequence may be from 1 to about 50 amino acids in length. Peptide sequences are not required when the first and second polypeptides have non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference. For example, the antigens in a fusion protein may be connected by a flexible polylinker  
30 such as Gly-Cys-Gly or Gly-Gly-Gly-Gly-Ser repeated 1 to 3 times (Bird *et al.*, 1988, Science 242:423-426; Chaudhary *et al.*, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070).

In one embodiment, such a protein is produced by recombinant expression of a nucleic acid encoding the protein. Such a fusion product can be made by ligating the appropriate nucleic acid sequences encoding the desired amino acid sequences to each other  
35 by methods known in the art, in the proper coding frame, and expressing the product by

methods known in the art. Alternatively, such a product may be made by protein synthetic techniques, *e.g.*, by use of a peptide synthesizer. Coding sequences for other molecules such as a cytokine or an adjuvant can be added to the fusion polynucleotide as well.

## 5        5.5.    PRODUCTION OF FUSION PROTEINS

In order to produce a *M. tuberculosis* fusion protein of the invention, the nucleotide sequence coding for the protein, or a functional equivalent, is inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of the inserted coding sequence. The host cells or cell lines transfected or  
10 transformed with recombinant expression vectors can be used for a variety of purposes. These include, but are not limited to, large scale production of the fusion protein.

Methods which are well known to those skilled in the art can be used to construct expression vectors containing a fusion coding sequence and appropriate transcriptional/translational control signals. These methods include *in vitro* recombinant  
15 DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See, *e.g.*, the techniques described in Sambrook et al., 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. and Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, N.Y.). RNA capable of encoding a polypeptide may also be chemically synthesized (Gait,  
20 *ed.*, 1984, Oligonucleotide Synthesis, IRL Press, Oxford).

### 5.5.1.    EXPRESSION SYSTEMS

A variety of host-expression vector systems may be utilized to express a fusion protein coding sequence. These include, but are not limited to, microorganisms such as  
25 bacteria (*e.g.*, *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing a coding sequence; yeast (*e.g.*, *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing a coding sequence; insect cell systems infected with recombinant virus expres-  
sion vectors (*e.g.*, baculovirus) containing a coding sequence; plant cell systems infected  
30 with recombinant virus expression vectors (*e.g.*, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (*e.g.*, Ti plasmid) containing a coding sequence; or mammalian cell systems (*e.g.*, COS, CHO, BHK, 293, 3T3 cells). The expression elements of these systems vary in their strength and specificities.

35        Depending on the host/vector system utilized, any of a number of suitable



transcription and translation elements, including constitutive and inducible promoters, may be used in the expression vector. For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage  $\lambda$ , plac, ptrp, ptac (ptrp-lac hybrid promoter; cytomegalovirus promoter) and the like may be used; when cloning in insect cell systems, promoters such as the baculovirus polyhedron promoter may be used; when cloning in plant cell systems, promoters derived from the genome of plant cells (e.g., heat shock promoters; the promoter for the small subunit of RUBISCO; the promoter for the chlorophyll  $\alpha/\beta$  binding protein) or from plant viruses (e.g., the 35S RNA promoter of CaMV; the coat protein promoter of TMV) may be used; when cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used; when generating cell lines that contain multiple copies of a the antigen coding sequence, SV40-, BPV- and EBV-based vectors may be used with an appropriate selectable marker.

Bacterial systems are preferred for the expression of *M. tuberculosis* antigens. For *in vivo* delivery, a bacterium such as *Bacillus-Calmette-Guerrin* may be engineered to express a fusion polypeptide of the invention on its cell surface. A number of other bacterial expression vectors may be advantageously selected depending upon the use intended for the expressed products. For example, when large quantities of the fusion protein are to be produced for formulation of pharmaceutical compositions, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited to, the *E. coli* expression vector pUR278 (Ruther *et al.*, 1983, EMBO J. 2:1791), in which a coding sequence may be ligated into the vector in frame with the *lacZ* coding region so that a hybrid protein is produced; pIN vectors (Inouye and Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke and Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can be purified easily from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned fusion polypeptide of interest can be released from the GST moiety.

### 5.5.2. PROTEIN PURIFICATION

Once a recombinant protein is expressed, it can be identified by assays based on the

physical or functional properties of the product, including radioactive labeling of the product followed by analysis by gel electrophoresis, radioimmunoassay, ELISA, bioassays, etc.

Once the encoded protein is identified, it may be isolated and purified by standard methods including chromatography (*e.g.*, high performance liquid chromatography, ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. The actual conditions used will depend, in part, on factors such as net charge, hydrophobicity, hydrophilicity, etc., and will be apparent to those having skill in the art. The functional properties may be evaluated using any suitable assay such as antibody binding, induction of T cell proliferation, stimulation of cytokine production such as IL2, IL-4 and IFN- $\gamma$ . For the practice of the present invention, it is preferred that each fusion protein is at least 80% purified from other proteins. It is more preferred that they are at least 90% purified. For *in vivo* administration, it is preferred that the proteins are greater than 95% purified.

15

#### 5.6. USES OF THE FUSION PROTEIN CODING SEQUENCE

The fusion protein coding sequence of the invention may be used to encode a protein product for use as an immunogen to induce and/or enhance immune responses to *M. tuberculosis*. In addition, such coding sequence may be ligated with a coding sequence of another molecule such as cytokine or an adjuvant. Such polynucleotides may be used *in vivo* as a DNA vaccine (U.S. Patent Nos. 5,589,466; 5,679,647; 5,703,055). In this embodiment of the invention, the polynucleotide expresses its encoded protein in a recipient to directly induce an immune response. The polynucleotide may be injected into a naive subject to prime an immune response to its encoded product, or administered to an infected or immunized subject to enhance the secondary immune responses.

In a preferred embodiment, a therapeutic composition comprises a fusion protein coding sequence or fragments thereof that is part of an expression vector. In particular, such a polynucleotide contains a promoter operably linked to the coding region, said promoter being inducible or constitutive, and, optionally, tissue-specific. In another embodiment, a polynucleotide contains a coding sequence flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the coding sequence (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra *et al.*, 1989, Nature 342:435-438).

Delivery of the nucleic acid into a subject may be either direct, in which case the subject is directly exposed to the nucleic acid or nucleic acid-carrying vector, or indirect, in

which case, cells are first transformed with the nucleic acid *in vitro*, then transplanted into the subject. These two approaches are known, respectively, as *in vivo* or *ex vivo* gene transfer.

In a specific embodiment, the nucleic acid is directly administered *in vivo*, where it is expressed to produce the encoded fusion protein product. This can be accomplished by any of numerous methods known in the art, *e.g.*, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, *e.g.*, by infection using a defective or attenuated retroviral or other viral vector (*see*, U.S. Patent No. 4,980,286), or by direct injection of naked DNA, or by use of microparticle bombardment (*e.g.*, a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules (United States Patent Nos. 5,407,609; 5,853,763; 5,814,344 and 5,820,883), or by administering it in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (*see, e.g.*, Wu and Wu, 1987, J. Biol. Chem. 262:4429-4432) which can be used to target cell types specifically expressing the receptors, etc. In another embodiment, a nucleic acid-ligand complex can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted *in vivo* for cell specific uptake and expression, by targeting a specific receptor (*see, e.g.*, PCT Publications WO 92/06180 dated April 16, 1992; WO 92/22635 dated December 23, 1992; WO92/20316 dated November 26, 1992; WO93/14188 dated July 22, 1993; WO 93/20221 dated October 14, 1993). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, 1989, Proc. Natl. Acad. Sci. USA 86:8932-8935; Zijlstra *et al.*, 1989, Nature 342:435-438).

In a specific embodiment, a viral vector such as a retroviral vector can be used (*see*, Miller *et al.*, 1993, Meth. Enzymol. 217:581-599). Retroviral vectors have been modified to delete retroviral sequences that are not necessary for packaging of the viral genome and integration into host cell DNA. A fusion coding sequence is cloned into the vector, which facilitates delivery of the nucleic acid into a recipient. More detail about retroviral vectors can be found in Boesen *et al.*, 1994, Biotherapy 6:291-302, which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes *et al.*, 1994, J. Clin. Invest. 93:644-651; Kiem *et al.*, 1994, Blood 83:1467-1473; Salmons and Gunzberg, 1993, Human Gene Therapy 4:129-

141; and Grossman and Wilson, 1993, Curr. Opin. in Genetics and Devel. 3:110-114.

Adenoviruses are other viral vectors that can be used in gene therapy. Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for  
5 adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Adeno-associated virus (AAV) has also been proposed for use in *in vivo* gene transfer (Walsh *et al.*, 1993, Proc. Soc. Exp. Biol. Med. 204:289-300.

Another approach involves transferring a construct to cells in tissue culture by such  
10 methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a subject.

In this embodiment, the nucleic acid is introduced into a cell prior to administration  
15 *in vivo* of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection, electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the  
20 introduction of foreign genes into cells (see *e.g.*, Loeffler and Behr, 1993, Meth. Enzymol. 217:599-618; Cohen *et al.*, 1993, Meth. Enzymol. 217:618-644; Cline, 1985, Pharmac. Ther. 29:69-92) and may be used in accordance with the present invention.

The polynucleotides of the invention may also be used in the diagnosis of tuberculosis for detection of polynucleotide sequences specific to *M. tuberculosis* in a  
25 patient. Such detection may be accomplished, for example, by isolating polynucleotides from a biological sample obtained from a patient suspected of being infected with the bacteria. Upon isolation of polynucleotides from the biological sample, a labeled polynucleotide of the invention that is complementary to one or more of the polynucleotides, will be allowed to hybridize to polynucleotides in the biological sample  
30 using techniques of nucleic acid hybridization known to those of ordinary skill in the art. For example, such hybridization may be carried out in solution or with one hybridization partner on a solid support.

#### 5.7. THERAPEUTIC AND PROPHYLACTIC USES OF THE FUSION PROTEIN

Purified or partially purified fusion proteins or fragments thereof may be formulated as a vaccine or therapeutic composition. Such composition may include adjuvants to enhance immune responses. In addition, such proteins may be further suspended in an oil emulsion to cause a slower release of the proteins *in vivo* upon injection. The optimal ratios of each component in the formulation may be determined by techniques well known to those skilled in the art.

Any of a variety of adjuvants may be employed in the vaccines of this invention to enhance the immune response. Most adjuvants contain a substance designed to protect the antigen from rapid catabolism, such as aluminum hydroxide or mineral oil, and a nonspecific stimulator of immune responses, such as lipid A, *Bordetella pertussis* or *Mycobacterium tuberculosis*. Suitable adjuvants are commercially available and include, for example, Freund's Incomplete Adjuvant and Freund's Complete Adjuvant (Difco Laboratories) and Merck Adjuvant 65 (Merck and Company, Inc., Rahway, NJ). Other suitable adjuvants include alum, biodegradable microspheres, monophosphoryl lipid A, quil A, SBAS1c, SBAS2 (Ling et al., 1997, Vaccine 15:1562-1567), SBAS7 and Al(OH)<sub>3</sub>.

In the vaccines of the present invention, it is preferred that the adjuvant induces an immune response comprising Th1 aspects. Suitable adjuvant systems include, for example, a combination of monophosphoryl lipid A, preferably 3-de-O-acylated monophosphoryl lipid A (3D-MLP) together with an aluminum salt. An enhanced system involves the combination of a monophosphoryl lipid A and a saponin derivative, particularly the combination of 3D-MLP and the saponin QS21 as disclosed in WO 94/00153, or a less reactogenic composition where the QS21 is quenched with cholesterol as disclosed in WO 96/33739. Previous experiments have demonstrated a clear synergistic effect of combinations of 3D-MLP and QS21 in the induction of both humoral and Th1 type cellular immune responses. A particularly potent adjuvant formulation involving QS21, 3D-MLP and tocopherol in an oil-in-water emulsion is described in WO 95/17210 and is a preferred formulation.

Formulations containing an antigen of the present invention may be administered to a subject *per se* or in the form of a pharmaceutical or therapeutic composition. Pharmaceutical compositions comprising the proteins may be manufactured by means of conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or lyophilizing processes. Pharmaceutical compositions may be formulated in conventional manner using one or more physiologically acceptable carriers, diluents, excipients or auxiliaries which facilitate processing of the polypeptides into preparations which can be used pharmaceutically. Proper formulation is dependent upon

the route of administration chosen.

For topical administration, the proteins may be formulated as solutions, gels, ointments, creams, suspensions, etc. as are well-known in the art.

Systemic formulations include those designed for administration by injection, *e.g.* subcutaneous, intravenous, intramuscular, intrathecal or intraperitoneal injection, as well as those designed for transdermal, transmucosal, oral or pulmonary administration.

For injection, the proteins may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. The solution may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the proteins may be in powder form for constitution with a suitable vehicle, *e.g.*, sterile pyrogen-free water, before use.

For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

For oral administration, a composition can be readily formulated by combining the proteins with pharmaceutically acceptable carriers well known in the art. Such carriers enable the proteins to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a subject to be treated. For oral solid formulations such as, for example, powders, capsules and tablets, suitable excipients include fillers such as sugars, such as lactose, sucrose, mannitol and sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.

If desired, solid dosage forms may be sugar-coated or enteric-coated using standard techniques.

For oral liquid preparations such as, for example, suspensions, elixirs and solutions, suitable carriers, excipients or diluents include water, glycols, oils, alcohols, etc.

Additionally, flavoring agents, preservatives, coloring agents and the like may be added.

For buccal administration, the proteins may take the form of tablets, lozenges, etc. formulated in conventional manner.

For administration by inhalation, the proteins for use according to the present invention are conveniently delivered in the form of an aerosol spray from pressurized packs or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane,

trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of, *e.g.*, gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the proteins and a suitable

5 powder base such as lactose or starch.

The proteins may also be formulated in rectal or vaginal compositions such as suppositories or retention enemas, *e.g.*, containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the proteins may also be  
10 formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the proteins may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

15 Alternatively, other pharmaceutical delivery systems may be employed. Liposomes and emulsions are well known examples of delivery vehicles that may be used to deliver an antigen. Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity. The fusion proteins may also be encapsulated in microspheres (United States Patent Nos. 5,407,609; 5,853,763; 5,814,344  
20 and 5,820,883). Additionally, the proteins may be delivered using a sustained-release system, such as semipermeable matrices of solid polymers containing the therapeutic or vaccinating agent. Various sustained-release materials have been established and are well known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the proteins for a few weeks up to over 100 days. Depending on  
25 the chemical nature and the biological stability of the reagent, additional strategies for protein stabilization may be employed.

Determination of an effective amount of the fusion protein for inducing an immune response in a subject is well within the capabilities of those skilled in the art, especially in light of the detailed disclosure provided herein.

30 An effective dose can be estimated initially from *in vitro* assays. For example, a dose can be formulated in animal models to achieve an induction of an immune response using techniques that are well known in the art. One having ordinary skill in the art could readily optimize administration to humans based on animal data. Dosage amount and interval may be adjusted individually. For example, when used as a vaccine, the  
35 polypeptides and/or polynucleotides of the invention may be administered in about 1 to 3

doses for a 1-36 week period. Preferably, 3 doses are administered, at intervals of about 3-4 months, and booster vaccinations may be given periodically thereafter. Alternate protocols may be appropriate for individual patients. A suitable dose is an amount of polypeptide or DNA that, when administered as described above, is capable of raising an immune response  
5 in an immunized patient sufficient to protect the patient from *M. tuberculosis* infection for at least 1-2 years. In general, the amount of polypeptide present in a dose (or produced *in situ* by the DNA in a dose) ranges from about 1 pg to about 100 mg per kg of host, typically from about 10 pg to about 1 mg, and preferably from about 100 pg to about 1 µg. Suitable dose range will vary with the size of the patient, but will typically range from about 0.1 mL  
10 to about 5 mL.

### 5.8 DIAGNOSTIC USES OF THE FUSION PROTEIN

The fusion polypeptides of the invention are useful in the diagnosis of tuberculosis infection *in vitro* and *in vivo*. The ability of a polypeptide of the invention to induce cell  
15 proliferation or cytokine production can be assayed by the methods disclosed in Section 5.2, *supra*.

In another aspect, this invention provides methods for using one or more of the fusion polypeptides to diagnose tuberculosis using a skin test *in vivo*. As used herein, a skin test is any assay performed directly on a patient in which a delayed-type hypersensitivity  
20 (DTH) reaction (such as swelling, reddening or dermatitis) is measured following intradermal injection of one or more polypeptides as described above. Such injection may be achieved using any suitable device sufficient to contact the polypeptide with dermal cells of the patient, such as, for example, a tuberculin syringe or 1 mL syringe. Preferably, the reaction is measured at least about 48 hours after injection, more preferably about 48 to  
25 about 72 hours after injection.

The DTH reaction is a cell-mediated immune response, which is greater in patients that have been exposed previously to the test antigen (*i.e.*, the immunogenic portion of the polypeptide employed, or a variant thereof). The response may be measured visually, using a ruler. In general, a response that is greater than about 0.5 cm in diameter, preferably  
30 greater than about 1.0 cm in diameter, is a positive response, indicative of tuberculosis infection, which may or may not be manifested as an active disease.

The fusion polypeptides of this invention are preferably formulated, for use in a skin test, as pharmaceutical compositions containing a polypeptide and a physiologically acceptable carrier. Such compositions typically contain one or more of the above  
35 polypeptides in an amount ranging from about 1 µg to about 100 µg, preferably from about



10 µg to about 50 µg in a volume of 0.1 mL. Preferably, the carrier employed in such pharmaceutical compositions is a saline solution with appropriate preservatives, such as phenol and/or Tween 80™.

In another aspect, the present invention provides methods for using the polypeptides  
5 to diagnose tuberculosis. In this aspect, methods are provided for detecting *M. tuberculosis* infection in a biological sample using the fusion polypeptides alone or in combination. As used herein, a "biological sample" is any antibody-containing sample obtained from a patient. Preferably, the sample is whole blood, sputum, serum, plasma, saliva cerebrospinal fluid or urine. More preferably, the sample is a blood, serum or plasma sample obtained  
10 from a patient or a blood supply. The polypeptide(s) are used in an assay, as described below, to determine the presence or absence of antibodies to the polypeptide(s) in the sample relative to a predetermined cut-off value. The presence of such antibodies indicates previous sensitization to mycobacterial antigens which may be indicative of tuberculosis.

In embodiments in which more than one fusion polypeptide is employed, the  
15 polypeptides used are preferably complementary (*i.e.*, one component polypeptide will tend to detect infection in samples where the infection would not be detected by another component polypeptide). Complementary polypeptides may generally be identified by using each polypeptide individually to evaluate serum samples obtained from a series of patients known to be infected with *M. tuberculosis*. After determining which samples test positive  
20 (as described below) with each polypeptide, combinations of two or more fusion polypeptides may be formulated that are capable of detecting infection in most, or all, of the samples tested. Such polypeptides are complementary. Approximately 25-30% of sera from tuberculosis-infected individuals are negative for antibodies to any single protein. Complementary polypeptides may, therefore, be used in combination to improve sensitivity  
25 of a diagnostic test.

There are a variety of assay formats known to those of ordinary skill in the art for using one or more polypeptides to detect antibodies in a sample. *See, e.g.*, Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory, 1988, which is incorporated herein by reference. In a preferred embodiment, the assay involves the use of  
30 polypeptide immobilized on a solid support to bind to and remove the antibody from the sample. The bound antibody may then be detected using a detection reagent that contains a reporter group. Suitable detection reagents include antibodies that bind to the antibody/polypeptide complex and free polypeptide labeled with a reporter group (*e.g.*, in a semi-competitive assay). Alternatively, a competitive assay may be utilized, in which an  
35 antibody that binds to the polypeptide is labeled with a reporter group and allowed to bind

to the immobilized antigen after incubation of the antigen with the sample. The extent to which components of the sample inhibit the binding of the labeled antibody to the polypeptide is indicative of the reactivity of the sample with the immobilized polypeptide.

The solid support may be any solid material known to those of ordinary skill in the art to which the antigen may be attached. For example, the solid support may be a test well in a microtiter plate or a nitrocellulose or other suitable membrane. Alternatively, the support may be a bead or disc, such as glass, fiberglass, latex or a plastic material such as polystyrene or polyvinylchloride. The support may also be a magnetic particle or a fiber optic sensor, such as those disclosed, for example, in U.S. Patent No. 5,359,681.

The polypeptides may be bound to the solid support using a variety of techniques known to those of ordinary skill in the art. In the context of the present invention, the term "bound" refers to both noncovalent association, such as adsorption, and covalent attachment (which may be a direct linkage between the antigen and functional groups on the support or may be a linkage by way of a cross-linking agent). Binding by adsorption to a well in a microtiter plate or to a membrane is preferred. *In* such cases, adsorption may be achieved by contacting the polypeptide, in a suitable buffer, with the solid support for a suitable amount of time. The contact time varies with temperature, but is typically between about 1 hour and 1 day. In general, contacting a well of a plastic microtiter plate (such as polystyrene or polyvinylchloride) with an amount of polypeptide ranging from about 10 ng to about 1  $\mu$ g, and preferably about 100 ng, is sufficient to bind an adequate amount of antigen.

Covalent attachment of polypeptide to a solid support may generally be achieved by first reacting the support with a bifunctional reagent that will react with both the support and a functional group, such as a hydroxyl or amino group, on the polypeptide. For example, the polypeptide may be bound to supports having an appropriate polymer coating using benzoquinone or by condensation of an aldehyde group on the support with an amine and an active hydrogen on the polypeptide (*see, e.g.*, Pierce Immunotechnology Catalog and Handbook, 1991, at A12-A13).

In certain embodiments, the assay is an enzyme linked immunosorbent assay (ELISA). This assay may be performed by first contacting a fusion polypeptide antigen that has been immobilized on a solid support, commonly the well of a microtiter plate, with the sample, such that antibodies to the polypeptide within the sample are allowed to bind to the immobilized polypeptide. Unbound sample is then removed from the immobilized polypeptide and a detection reagent capable of binding to the immobilized antibody-polypeptide complex is added. The amount of detection reagent that remains bound to the solid support is then determined using a method appropriate for the specific detection

reagent.

More specifically, once the polypeptide is immobilized on the support as described above, the remaining protein binding sites on the support are typically blocked. Any suitable blocking agent known to those of ordinary skill in the art, such as bovine serum albumin or Tween 20™ (Sigma Chemical Co., St. Louis, MO) may be employed. The immobilized polypeptide is then incubated with the sample, and antibody is allowed to bind to the antigen. The sample may be diluted with a suitable diluent, such as phosphate-buffered saline (PBS) prior to incubation. In general, an appropriate contact time is that period of time that is sufficient to detect the presence of antibody within a *M. tuberculosis*-infected sample. Preferably, the contact time is sufficient to achieve a level of binding that is at least 95% of that achieved at equilibrium between bound and unbound antibody. Those of ordinary skill in the art will recognize that the time necessary to achieve equilibrium may be readily determined by assaying the level of binding that occurs over a period of time. At room temperature, an incubation time of about 30 minutes is generally sufficient.

Unbound sample may then be removed by washing the solid support with an appropriate buffer, such as PBS containing 0.1% Tween 20™. Detection reagent may then be added to the solid support. An appropriate detection reagent is any compound that binds to the immobilized antibody-polypeptide complex and that can be detected by any of a variety of means known to those in the art. Preferably, the detection reagent contains a binding agent (for example, Protein A, Protein G, lectin or free antigen) conjugated to a reporter group. Preferred reporter groups include enzymes (such as horseradish peroxidase), substrates, cofactors, inhibitors, dyes, radionuclides, luminescent groups, fluorescent groups, biotin and colloidal particles, such as colloidal gold and selenium. The conjugation of binding agent to reporter group may be achieved using standard methods known to those of ordinary skill in the art. Common binding agents may also be purchased conjugated to a variety of reporter groups from many commercial sources (*e.g.*, Zymed Laboratories, San Francisco, CA, and Pierce, Rockford, IL).

The detection reagent is then incubated with the immobilized antibody-polypeptide complex for an amount of time sufficient to detect the bound antibody. An appropriate amount of time may generally be determined from the manufacturer's instructions or by assaying the level of binding that occurs over a period of time. Unbound detection reagent is then removed and bound detection reagent is detected using the reporter group. The method employed for detecting the reporter group depends upon the nature of the reporter group. For radioactive groups, scintillation counting or autoradiographic methods are generally appropriate. Spectroscopic methods may be used to detect dyes, luminescent

groups and fluorescent groups. Biotin may be detected using avidin, coupled to a different reporter group (commonly a radioactive or fluorescent group or an enzyme). Enzyme reporter groups may generally be detected by the addition of substrate (generally for a specific period of time), followed by spectroscopic or other analysis of the reaction products.

To determine the presence or absence of anti-*M. tuberculosis* antibodies in the sample, the signal detected from the reporter group that remains bound to the solid support is generally compared to a signal that corresponds to a predetermined cut-off value. In one preferred embodiment, the cut-off value is the average mean signal obtained when the immobilized antigen is incubated with samples from an uninfected patient. In general, a sample generating a signal that is three standard deviations above the predetermined cut-off value is considered positive for tuberculosis. In an alternate preferred embodiment, the cut-off value is determined using a Receiver Operator Curve, according to the method of Sackett et al., 1985, *Clinical Epidemiology: A Basic Science for Clinical Medicine*, Little Brown and Co., pp. 106-107. Briefly, in this embodiment, the cut-off value may be determined from a plot of pairs of true positive rates (*i.e.*, sensitivity) and false positive rates (100%-specificity) that correspond to each possible cut-off value for the diagnostic test result. The cut-off value on the plot that is the closest to the upper left-hand corner (*i.e.*, the value that encloses the largest area) is the most accurate cut-off value, and a sample generating a signal that is higher than the cut-off value determined by this method may be considered positive. Alternatively, the cut-off value may be shifted to the left along the plot, to minimize the false positive rate, or to the right, to minimize the false negative rate. In general, a sample generating a signal that is higher than the cut-off value determined by this method is considered positive for tuberculosis.

In a related embodiment, the assay is performed in a rapid flow-through or strip test format, wherein the antigen is immobilized on a membrane, such as nitrocellulose. In the flow-through test, antibodies within the sample bind to the immobilized polypeptide as the sample passes through the membrane. A detection reagent (*e.g.*, protein A-colloidal gold) then binds to the antibody-polypeptide complex as the solution containing the detection reagent flows through the membrane. The detection of bound detection reagent may then be performed as described above. In the strip test format, one end of the membrane to which polypeptide is bound is immersed in a solution containing the sample. The sample migrates along the membrane through a region containing detection reagent and to the area of immobilized polypeptide. Concentration of detection reagent at the polypeptide indicates the presence of anti-*M. tuberculosis* antibodies in the sample. Typically, the concentration

of detection reagent at that site generates a pattern, such as a line, that can be read visually. The absence of such a pattern indicates a negative result. In general, the amount of polypeptide immobilized on the membrane is selected to generate a visually discernible pattern when the biological sample contains a level of antibodies that would be sufficient to  
5 generate a positive signal in an ELISA, as discussed above. Preferably, the amount of polypeptide immobilized on the membrane ranges from about 5 ng to about 1 µg, and more preferably from about 50 ng to about 500 ng. Such tests can typically be performed with a very small amount (*e.g.*, one drop) of patient serum or blood.

The invention having been described, the following examples are offered by way of  
10 illustration and not limitation.

## 6. EXAMPLE: FUSION PROTEINS OF *M. TUBERCULOSIS* ANTIGENS RETAIN IMMUNOGENICITY OF THE INDIVIDUAL COMPONENTS

---

15

### 6.1. MATERIALS AND METHODS

#### 6.1.1. CONSTRUCTION OF FUSION PROTEINS

Coding sequences of *M. tuberculosis* antigens were modified by PCR in order to  
20 facilitate their fusion and subsequent expression of fusion protein. DNA amplification was performed using 10 µl 10X Pfu buffer, 2 µl 10 mM dNTPs, 2 µl each of the PCR primers at 10 µM concentration, 81.5 µl water, 1.5 µl Pfu DNA polymerase (Stratagene, La Jolla, CA) and 1 µl DNA at either 70 ng/µl (for TbRa3 antigen) or 50 ng/µl (for 38 kD and Tb38-1 antigens). For TbRa3 antigen, denaturation at 94°C was performed for 2 min, followed by  
25 40 cycles of 96°C for 15 sec and 72°C for 1 min, and lastly by 72°C for 4 min. For 38 kD antigen, denaturation at 96°C was performed for 2 min, followed by 40 cycles of 96°C for 30 sec, 68°C for 15 sec and 72°C for 3 min, and finally by 72°C for 4 min. For Tb38-1 antigen, denaturation at 94°C for 2 min was followed by 10 cycles of 96°C for 15 sec, 68°C for 15 sec and 72°C for 1.5 min, 30 cycles of 96°C for 15 sec, 64°C for 15 sec and 72°C for  
30 1.5, and finally by 72°C for 4 min.

Following digestion with a restriction endonuclease to yield the desired cohesive or blunt ends, a polynucleotide specific for each fusion polypeptide was ligated into an expression plasmid. Each resulting plasmid contained the coding sequences of the individual antigens of each fusion polypeptide. The expression vectors used were pET-12b  
35 and pT7<sup>+</sup>L2 IL 1.

Three coding sequences for antigens Ra12, TbH9 and Ra35 were ligated to encode one fusion protein (SEQ ID NOS:1 and 2) (Fig. 1A and 2B). Another three coding sequences for antigens Erd14, DPV and MTI were ligated to encode a second fusion protein (SEQ ID NOS:3 and 4) (Fig. 2). Three coding sequences for antigens TbRa3, 38kD and Tb38-1 were ligated to encode one fusion protein (SEQ ID NOS:5 and 6) (Fig. 3A - 3D). Two coding sequences for antigens TbH9 and Tb38-1 were ligated to encode one fusion protein (SEQ ID NOS:7 and 8) (Fig. 4A - 4D). Four coding sequences for antigens TbRa3, 38kD, Tb38-1 and DPEP were ligated to encode one fusion protein (SEQ ID NOS:9 and 10) (Fig. 5A - 5J). Five coding sequences for antigens Erd14, DPV, MTI, MSL and MTCC2 were ligated to encode one fusion protein (SEQ ID NOS:11 and 12) (Fig. 6A and 6B). Four coding sequences for antigens Erd14, DPV, MTI and MSL were ligated to encode one fusion protein (SEQ ID NOS:13 and 14) (Fig. 7A and 7B). Four coding sequences for antigens DPV, MTI, MSL and MTCC2 were ligated to encode one fusion protein (SEQ ID NOS:15 and 16) (Fig. 8A and 8B). Three coding sequences for antigens DPV, MTI and MSL were ligated to encode one fusion protein (SEQ ID NOS:17 and 18) (Fig. 9A and 9B). Three coding sequences for antigens TbH9, DPV and MTI were ligated to encode one fusion protein (SEQ ID NOS:19 and 20) (Fig. 10A and 10B). Three coding sequences for antigens Erd14, DPV and MTI were ligated to encode one fusion protein (SEQ ID NOS:21 and 22) (Fig. 11A and 11B). Two coding sequences for antigens TbH9 and Ra35 were ligated to encode one fusion protein (SEQ ID NOS:23 and 24) (Fig. 12A and 12B). Two coding sequences for antigens Ra12 and DPPD were ligated to encode one fusion protein (SEQ ID NOS:25 and 26) (Fig. 13A and 13B).

The recombinant proteins were expressed in *E. coli* with six histidine residues at the amino-terminal portion using the pET plasmid vector (pET-17b) and a T7 RNA polymerase expression system (Novagen, Madison, WI). *E. coli* strain BL21 (DE3) pLysE (Novagen) was used for high level expression. The recombinant (His-Tag) fusion proteins were purified from the soluble supernatant or the insoluble inclusion body of 500 ml of IPTG induced batch cultures by affinity chromatography using the one step QIAexpress Ni-NTA Agarose matrix (QIAGEN, Chatsworth, CA) in the presence of 8M urea. Briefly, 20 ml of an overnight saturated culture of BL21 containing the pET construct was added into 500 ml of 2xYT media containing 50 µg/ml ampicillin and 34 µg/ml chloramphenicol, grown at 37°C with shaking. The bacterial cultures were induced with 2mM IPTG at an OD<sub>560</sub> of 0.3 and grown for an additional 3 h (OD = 1.3 to 1.9). Cells were harvested from 500 ml batch cultures by centrifugation and resuspended in 20 ml of binding buffer (0.1 M sodium phosphate, pH 8.0; 10 mM Tris-HCl, pH 8.0) containing 2mM PMSF and 20 µg/ml

leupeptin plus one complete protease inhibitor tablet (Boehringer Mannheim) per 25 ml. *E. coli* was lysed by freeze-thaw followed by brief sonication, then spun at 12 k rpm for 30 min to pellet the inclusion bodies.

The inclusion bodies were washed three times in 1% CHAPS in 10 mM Tris-HCl (pH 8.0). This step greatly reduced the level of contaminating LPS. The inclusion body was finally solubilized in 20 ml of binding buffer containing 8 M urea or 8M urea was added directly into the soluble supernatant. Recombinant fusion proteins with His-Tag residues were batch bound to Ni-NTA agarose resin (5 ml resin per 500 ml inductions) by rocking at room temperature for 1 h and the complex passed over a column. The flow through was passed twice over the same column and the column washed three times with 30 ml each of wash buffer (0.1 M sodium phosphate and 10 mM Tris-HCL, pH 6.3) also containing 8 M urea. Bound protein was eluted with 30 ml of 150 mM imidazole in wash buffer and 5 ml fractions collected. Fractions containing each recombinant fusion protein were pooled, dialyzed against 10 mM TrisHCl (pH 8.0) bound one more time to the Ni-NTA matrix, eluted and dialyzed in 10 mM Tris-HCL (pH 7.8). The yield of recombinant protein varies from 25 - 150 mg per liter of induced bacterial culture with greater than 98% purity. Recombinant proteins were assayed for endotoxin contamination using the *Limulus* assay (BioWhittaker) and were shown to contain < 10 E.U./mg.

#### 20                    **6.1.2. T-CELL PROLIFERATION ASSAY**

Purified fusion polypeptides were tested for the ability to induce T-cell proliferation in peripheral blood mononuclear cell (PBMC) preparations. The PBMCs from donors known to be PPD skin test positive and whose T-cells were shown to proliferate in response to PPD and crude soluble proteins from *M. tuberculosis* were cultured in RPMI 1640 supplemented with 10% pooled human serum and 50 µg/ml gentamicin. Purified polypeptides were added in duplicate at concentrations of 0.5 to 10 µg/ml. After six days of culture in 96-well round-bottom plates in a volume of 200 µl, 50 µl of medium was removed from each well for determination of IFN-γ levels, as described below in Section 6.1.3. The plates were then pulsed with 1 µCi/well of tritiated thymidine for a further 18 hours, harvested and tritium uptake determined using a gas scintillation counter. Fractions that resulted in proliferation in both replicates three fold greater than the proliferation observed in cells cultured in medium alone were considered positive.

#### 35                    **6.1.3. INTERFERON-γ ASSAY**

Spleens from mice were removed aseptically and single cell suspension prepared in

complete RPMI following lysis of red blood cells. 100  $\mu$ l of cells ( $2 \times 10^5$  cells) were plated per well in a 96-well flat bottom microtiter plate. Cultures were stimulated with the indicated recombinant proteins for 24h and the supernatant assayed for IFN- $\gamma$ .

The levels of supernatant IFN- $\gamma$  was analysed by sandwich ELISA, using antibody  
5 pairs and procedures available from PharMingen. Standard curves were generated using recombinant mouse cytokines. ELISA plates (Corning) were coated with 50  $\mu$ l/well (1  $\mu$ g/ml, in 0.1 M bicarbonate coating buffer, pH9.6) of a cytokine capture mAb (rat anti-mouse IFN- $\gamma$  (PharMingen; Cat. # 18181D)), and incubated for 4 h at room temp. Shake out plate contents and block with PBS-0.05% Tween, 1.0% BSA (200  $\mu$ l/well) overnight at  
10 4°C and washed for 6X in PBS-0.1% Tween. Standards (mouse IFN- $\gamma$ ) and supernatant samples diluted in PBS-0.05% Tween, 0.1% BSA were then added for 2 hr at room temp. The plates were washed as above and then incubated for 2 hr at room temperature with 100  $\mu$ l/well of a second Ab (biotin rat  $\alpha$  mouse IFN- $\gamma$  (Cat. # 18112D; PharMingen) at 0.5  $\mu$ g/ml diluted in PBS-0.05% Tween, 0.1% BSA. After washing, plates were incubated with  
15 100  $\mu$ l/well of streptavidin-HRP (Zymed) at a 1:2500 dilution in PBS-0.05% Tween, 0.1% BSA at room temp for 1hr. The plates were washed one last time and developed with 100  $\mu$ l/well TMB substrate (3,3',5,5' — tetramethylbenzidine, Kirkegaard and Perry, Gaithersburg, MD) and the reaction stopped after color developed, with H<sub>2</sub>SO<sub>4</sub>, 50  $\mu$ l/well. Absorbance (OD) were determined at 450 nm using 570 nm as a reference wavelength and  
20 the cytokine concentration evaluated using the standard curve.

## 6.2. RESULTS

### 6.2.1. TRI-FUSION PROTEINS INDUCED IMMUNE RESPONSES

25 Three coding sequences for *M. tuberculosis* antigens were inserted into an expression vector for the production of a fusion protein. The antigens designated Ra12, TbH9 and Ra35 were produced as one recombinant fusion protein (Figure 1A and 1B). Antigens Erd14, DPV and MTI were produced as a second fusion protein (Figure 2). The two fusion proteins were affinity purified for use in *in vitro* and *in vivo* assays.

30 The two fusion proteins were tested for their ability to stimulate T cell responses from six PPD<sup>+</sup> subjects. When T cell proliferation was measured, both fusion proteins exhibited a similar reactivity pattern as their individual components (Figure 14A-14F). A similar result was obtained when IFN- $\gamma$  production was measured (Figure 15A-15F). For example, subject D160 responded to antigens TbH9 and MTI individually. Subject D160  
35 also responded to the fusion proteins that contained these antigens (Figure 14B and 15B).



In contrast, no T cell response from D160 was observed to other antigens individually. Another subject, D201, who did not react with antigens Erd14, DPV or MTI individually, was also unresponsive to the fusion protein containing these antigens. It should be noted that when the T cell responses to the individual components of the two fusion proteins were not particularly strong, the fusion proteins stimulated responses that were equal to or higher than that induced by the individual antigens in most cases.

The Ra12-TbH9-Ra35 tri-fusion protein was also tested as an immunogen *in vivo*. In these experiments, the fusion protein was injected into the footpads of mice for immunization. Each group of three mice received the protein in a different adjuvant formulation: SBAS1c, SBAS2 (Ling *et al.*, 1997, Vaccine 15:1562-1567), SBAS7 and AL(OH)<sub>3</sub>. After two subcutaneous immunizations at three week intervals, the animals were sacrificed one week later, and their draining lymph nodes were harvested for use as responder cells in T cell proliferation and cytokine production assays.

Regardless which adjuvant was used in the immunization, strong T cell proliferation responses were induced against TbH9 when it was used as an individual antigen (Figure 16A). Weaker responses were induced against Ra35 and Ra12 (Figure 16B and 16C). When the Ra12-TbH9-Ra35 fusion protein was used as immunogen, a response similar to that against the individual components was observed.

When cytokine production was measured, adjuvants SBAS1c and SBAS2 produced similar IFN- $\gamma$  (Figure 17) and IL-4 responses (Figure 18). However, the combination of SBAS7 and aluminum hydroxide produced the strongest IFN- $\gamma$  responses and the lowest level of IL-4 production for all three antigens. With respect to the humoral antibody response *in vivo*, Figure 19A-19F shows that the fusion protein elicited both IgG<sub>1</sub> and IgG<sub>2a</sub> antigen-specific responses when it was used with any of the three adjuvants.

Additionally, C57BL/6 mice were immunized with a combination of two expression constructs each containing Ra12-TbH9-Ra35 (Mtb32A) or Erd14-DPV-MTI (Mtb39A) coding sequence as DNA vaccines. The immunized animals exhibited significant protection against tuberculosis upon a subsequent aerosol challenge of live bacteria. Based on these results, a fusion construct of Mtb32A and Mtb39A coding sequences was made, and its encoded product tested in a guinea pig long term protection model. In these studies, guinea pigs were immunized with a single recombinant fusion protein or a mixture of Mtb32A and Mtb39A proteins in formulations containing an adjuvant. Figure 20A-20C shows that guinea pigs immunized with the fusion protein in SBAS1c or SBAS2 were better protected against the development of tuberculosis upon subsequent challenge, as compared to animals immunized with the two antigens in a mixture in the same adjuvant formulation. The fusion

proteins in SBAS2 formulation afforded the greatest protection in the animals. Thus, fusion proteins of various *M. tuberculosis* antigens may be used as more effective immunogens in vaccine formulations than a mixture of the individual components.

5                   **6.2.2. BI-FUSION PROTEIN INDUCED IMMUNE RESPONSES**

A bi-fusion fusion protein containing the TbH-9 and Tb38-1 antigens without a hinge sequence was produced by recombinant methods. The ability of the TbH9-Tb38-1 fusion protein to induce T cell proliferation and IFN- $\gamma$  production was examined. PBMC from three donors were employed: one donor had been previously shown to respond to  
10 TbH9 but not to Tb38-1 (donor 131); one had been shown to respond to Tb38-1 but not to TbH9 (donor 184); and one had been shown to respond to both antigens (donor 201). The results of these studies demonstrate the functional activity of both the antigens in the fusion protein (Figures 21A and 21B, 22A and 22B, and 23A and 23B).

15                   **6.2.3. A TETRA-FUSION PROTEIN REACTED WITH TUBERCULOSIS PATIENT SERA**

A fusion protein containing TbRa3, 38KD antigen, Tb38-1 and DPEP was produced by recombinant methods. The reactivity of this tetra-fusion protein referred to as TbF-2 with sera from *M. tuberculosis*-infected patients was examined by ELISA. The results of  
20 these studies (Table 1) demonstrate that all four antigens function independently in the fusion protein.

One of skill in the art will appreciate that the order of the individual antigens within each fusion protein may be changed and that comparable activity would be expected provided that each of the epitopes is still functionally available. In addition, truncated  
25 forms of the proteins containing active epitopes may be used in the construction of fusion proteins.

The present invention is not to be limited in scope by the exemplified embodiments which are intended as illustrations of single aspects of the invention, and any clones, nucleotide or amino acid sequences which are functionally equivalent are within the scope  
30 of the invention. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims. It is also to be understood that all base pair sizes given for nucleotides are approximate and are used for purposes of description.

35                   All publications cited herein are incorporated by reference in their entirety.

TABLE 1  
REACTIVITY OF TbF-2 FUSION PROTEIN WITH TB AND NORMAL SERA

	Serum ID	Status	TbF OD450	Status	TbF-2 OD450	Status	ELISA Reactivity			
							38 kD	TbRa3	Tb38-I	DPEP
5	B931-40	TB	0.57	+	0.321	+	-	+	-	+
	B931-41	TB	0.601	+	0.396	+	+	+	+	-
	B931-109	TB	0.494	+	0.404	+	+	+	±±	-
	B931-132	TB	1.502	+	1.292	+	+	+	+	±±
	5004	TB	1.806	+	1.666	+	±±	±±	+	-
10	15004	TB	2.862	+	2.468	+	+	+	+	-
	39004	TB	2.443	+	1.722	+	+	+	+	-
	68004	TB	2.871	+	2.575	+	+	+	+	-
	99004	TB	0.691	+	0.971	+	-	±±	+	-
	107004	TB	0.875	+	0.732	+	-	±±	+	-
15	92004	TB	1.632	+	1.394	+	+	±±	±±	-
	97004	TB	1.491	+	1.979	+	+	±±	-	+
	118004	TB	3.182	+	3.045	+	+	±±	-	-
	173004	TB	3.644	+	3.578	+	+	+	+	-
	175004	TB	3.332	+	2.916	+	+	+	-	-
20	274004	TB	3.696	+	3.716	+	-	+	-	+
	276004	TB	3.243	+	2.56	+	-	-	+	-
	282004	TB	1.249	+	1.234	+	+	-	-	-
	289004	TB	1.373	+	1.17	+	-	+	-	-
	308004	TB	3.708	+	3.355	+	-	-	+	-
25	314004	TB	1.663	+	1.399	+	-	-	+	-
	317004	TB	1.163	+	0.92	+	+	-	-	-
	312004	TB	1.709	+	1.453	+	-	+	-	-
	380004	TB	0.238	-	0.461	+	-	±±	-	+
	451004	TB	0.18	-	0.2	-	-	-	-	±±
30	478004	TB	0.188	-	0.469	+	-	-	-	±±
	410004	TB	0.384	+	2.392	+	±±	-	-	+
	411004	TB	0.306	+	0.874	+	-	+	-	+
	421004	TB	0.357	+	1.456	+	-	+	-	+
	528004	TB	0.047	-	0.196	-	-	-	-	+
35	A6-87	Normal	0.094	-	0.063	-	-	-	-	-
	A6-88	Normal	0.214	-	0.19	-	-	-	-	-
	A6-89	Normal	0.248	-	0.125	-	-	-	-	-
	A6-90	Normal	0.179	-	0.206	-	-	-	-	-
	A6-91	Normal	0.135	-	0.151	-	-	-	-	-
	A6-92	Normal	0.064	-	0.097	-	-	-	-	-
	A6-93	Normal	0.072	-	0.098	-	-	-	-	-
	A6-94	Normal	0.072	-	0.064	-	-	-	-	-
	A6-95	Normal	0.125	-	0.159	-	-	-	-	-
	A6-96	Normal	0.121	-	0.12	-	-	-	-	-
Cut-off			0.284		0.266					

**WHAT IS CLAIMED IS:**

1. A purified polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24, said amino acid sequence may optionally contain one or more conservative amino acid substitutions.
2. A purified polypeptide encoded by a polynucleotide that hybridizes under moderately stringent conditions to a second polynucleotide which is complementary to a nucleotide sequence that encodes the amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24, said amino acid sequence induces an immune response to *M. tuberculosis*.
3. The polypeptide of Claim 2 which is a soluble polypeptide.
4. The polypeptide of Claim 2 which is produced by a recombinant DNA method.
5. The polypeptide of Claim 2 which is produced by a chemical synthetic method.
6. The polypeptide of Claim 2 which induces an antibody response.
7. The polypeptide of Claim 2 which induces a T cell response.
8. The polypeptide of Claim 2 which is fused with a second heterologous polypeptide.
9. A method of preventing tuberculosis, comprising administering to a subject an effective amount of the polypeptide of Claim 1.
10. A method of preventing tuberculosis, comprising administering to a subject an effective amount of the polypeptide of Claim 2.
11. A method of preventing tuberculosis, comprising administering to a subject an effective amount of a polynucleotide that encodes the polypeptide of Claim 2.

12. A pharmaceutical composition comprising the polypeptide of Claim 2.

13. A pharmaceutical composition comprising a polynucleotide that encodes the polypeptide of Claim 2.

5

10

15

20

25

30

35




FIG. 1A

2 / 47

TCGCGGAAAGAGGCGCCCGGCGAGATGCTGGCGCGCGTGGCGGTGGCGGAGATGGCGCGCGAGCGCGCGGTGGCGGTGAGTGGTGTGGTGGGTGGTGGG 1600  
A A E R C P G C H L C G L P V C C H C A R A G C G L S G V L R V P P  
Tb H9  
CGGACCGTATCTGATGCGCGCATCTCCGGCAGCGCGCGATATGCGCGCGCGCGCGTGGTGGCGAGCGCGTTCGCGCGACTTCGCGCGGTGGCGGTGGCG 1700  
R P Y V M P H S P A A G D I A P P A L S O C R F A O F P A L P L D  
Tb H9 Tb Ra35  
CGGTCCCGGATGGTGGCGCAAGTGGGGCCACAGGTGGTCAACATCAACACCAAACTGGCGTACAACAACCGCGTGGCGCGCGCGGACCGCGATCGTCATCG 1800  
P S A M V A O V G P O V V N I N T X L G Y N H A V G A C T G I V I  
Tb Ra35  
ATCCCAACCGTGTGCTGCTGACCAACAACACGTCGTCGGCGCGCGCGCGCGACATCAATGCGTTCAGCGTGGCGTGGCGCGCAACCTACGGCGTGGATGT 1900  
O P N C V V L T N N H V I A G A T D I N A F S V G S C O T Y G V O V  
Tb Ra35  
GGTGGGTATGACCGCACCCAGGATGTCGGGTGGTGGAGGTGGCGGTGGCGGTGGCGGTACCATCGCGCGCGATCGGTGGCGCGGTGGCGGTGGCGGTGGCG 2000  
V G Y D R T O D V A V L O L R G A G G L P S A A I G C G V A V G E  
Tb Ra35  
CGCTTCGTGGCGATGGCGAACACCGGTGGCGAGCGCGGGAACCGCGGTGGCGTGGCTGGCGAGGTGGTGGCGTGGCGCGCAACCGTGGAGCGGTGGCGAT 2100  
P F V A H G N S G C O C G T P R A V P G R V V A L G O T V O A S D  
Tb Ra35  
CGGTGACCGGTGGCGAAGAGACATGAACCGGTGATCCAGTTCGATCGCGCGATCGAGCGCGGTGATTCGGCGCGCGCGGTGGTCAACCGCGTACGACAT 2200  
S L T C A E E T L N G L I O F O A A I O P C O S C G P V V N G L C G  
Tb Ra35  
CGTGGTGGGTATCAACACCGCGCGGTGGTGGATATCCATCAGACTCGCGCGCGGTGGAGGAGATCGCGGTGTACCAACCGCGGAAA 2267  
V V C H N T A A S  
Tb Ra35

3 / 47

GATATACATATGCATCACCATCACCATCACATGCGCCACACCGCTTCCCGTTCAGCGCCACCGCGCGTCCCTCTTCCCGGAGCTTTCTGAGGTGTTCGCGG  
100  
H H H H H H H M A T T L P V O R H P R S L F P E F S E L F A  
ERD 14  
CTTCCCGTCAATTCGCGGACTCCGCGCCACCTTCGACACCGGTTGATGCGCGTGGAGACGAGATGAAAGAGGGGCGCTACGAGGTACCGCGGAGCT  
200  
A F P S F A G L R P T F D T R L H R L E D E H K E G R Y E V R A E L  
ERD 14  
TCCCGGGTTCGACCGCGACAAGGACGTGACATTATGGTCCGCGATGGTCAGCTCACCATCAAGGCGGAGCGCACCGAGCAGAAGGCACTTCGACGGTCCG  
300  
P G V O P D X D V O I H V R D G O L T I K A E R T E O X O F O G R  
ERD 14  
TCGGAATTCGGTACGGTTCCTTCGTTCCGACCGGTGTGCTGCGCGTACGCTGCTCAGCAGGACGACATTAAGGCCACCTACGACAAGGCCATTCTTACTG  
400  
S E F A Y G S F V R T V S L P V G A O E O D I K A T Y O X C I L I  
ERD 14  
TGTGGTGGCGGTTTCGGAAGGGAAGCCAAACCGAAAAGCACATTGATCCGCTCCACCAACAAGCTTGATCCCGTGGACGGCGCTATTACACCACTG  
500  
V S V A V S E G K P T E X H I O I R S T N K L D P Y D A V I N T T C  
ERD 14 HindII DPV  
CAATTACGGCCAGGTAGTAGCTGCGGTCAACGGGACGGATCCGCGGGCTCCCGCACAGTTCACCGGCTCAGCGGTGGCGGAGTCTATTTCGCAATTTC  
600  
H Y G O V V A A L N A T D P C A A A O F N A S P V A O S Y L R N F  
DPV  
CTCGCGGACCGCCACCTCAGCGCGCTGCCATGCGCGCGCAATTGCAAGCTGTGCGCGCGCGCGCACAGTACATCGCGCTTGTGAGTCCGTTCGCGCT  
700  
L A A P P P O R A A H A A O L O A V P C A A O Y I G L V E S V A C  
OPV  
CCTGCAACAACIATGAGTTCATGACGATTATATTACAGTTCGCGGACGTCAGCGCTCATGCGCGCATGATCCGCGCTCAGCGCGCTTCCTTCAGCGCGA  
800  
S C N N Y E L H T I N Y O F C O V D A H G A H I R A O A A S L E A E  
DPV SacI MTI  
GCATCAGGCCATCGTTCGTGATGTGTTGGCGCGCGGTGACTTTTGGCGCGCGCGGTTGCGTTCGCTTCAGGAGTTCATTACCCAGTTCGCGCGTAAC  
900  
H O A I V R D V L A A G D F W C C A C S V A C O E F I T O L C R N  
MTI  
TTCAGGTGATCTACGAGCAGGCAACGCGCGCAGAGGCTGAGGCTCCCGCGCAACATGCGCGCAACGAGACCGCGCTCCGCTCCAGTTCGCG  
1000  
F O V I T E O A N A H G O X V O A A G N H M A O T D S A V G S S W  
MTI  
CCTAGTAACCGCGCGCGAGTGTGCTGGAATTCTGAGATATCCATCAGCTGCGCGCGCGCTGAGGAGATCCGCTGCTA  
1091

A [Spe I]

4

FIG. 2



TGTTCTTCGA CGGCAGGCTG GTGGAGGAAG GGCCCACCGA ACAGCTGTTC TCCTCGCCGA  
60

AGCATGCGGA AACCGCCCGA TACGTCGCCG GACTGTCGGG GGACGTCAAG GACGCCAAGC  
120

GCGGAAATTG AAGAGCACAG AAAGGTATGG C GTG AAA ATT CGT TTG CAT ACG  
172

Val Lys Ile Arg Leu His Thr  
1 5

CTG TTG GCC GTG TTG ACC GCT GCG CCG CTG CTG CTA GCA GCG GCG GGC  
220

Leu Leu Ala Val Leu Thr Ala Ala Pro Leu Leu Leu Ala Ala Ala Gly  
10 15 20

TGT GGC TCG AAA CCA CCG AGC GGT TCG CCT GAA ACG GGC GCC GGC GCC  
268

Cys Gly Ser Lys Pro Pro Ser Gly Ser Pro Glu Thr Gly Ala Gly Ala  
25 30 35

GGT ACT GTC GCG ACT ACC CCC GCG TCG TCG CCG GTG ACG TTG GCG GAG  
316

Gly Thr Val Ala Thr Thr Pro Ala Ser Ser Pro Val Thr Leu Ala Glu  
40 45 50 55

ACC GGT AGC ACG CTG CTC TAC CCG CTG TTC AAC CTG TGG GGT CCG GCC  
364

Thr Gly Ser Thr Leu Leu Tyr Pro Leu Phe Asn Leu Trp Gly Pro Ala  
60 65 70

TTT CAC GAG AGG TAT CCG AAC GTC ACG ATC ACC GCT CAG GGC ACC GGT  
412

Phe His Glu Arg Tyr Pro Asn Val Thr Ile Thr Ala Gln Gly Thr Gly  
75 80 85

TCT GGT GCC GGG ATC GCG CAG GCC GCC GCC GGG ACG GTC AAC ATT GGG  
460

Ser Gly Ala Gly Ile Ala Gln Ala Ala Ala Gly Thr Val Asn Ile Gly  
90 95 100

Fig. 3A

5 / 47

GCC TCC GAC GCC TAT CTG TCG GAA GGT GAT ATG GCC GCG CAC AAG GGG  
 508  
 Ala Ser Asp Ala Tyr Leu Ser Glu Gly Asp Met Ala Ala His Lys Gly  
 105 110 115

CTG ATG AAC ATC GCG CTA GCC ATC TCC GCT CAG CAG GTC AAC TAC AAC  
 556  
 Leu Met Asn Ile Ala Leu Ala Ile Ser Ala Gln Gln Val Asn Tyr Asn  
 120 125 130 135

CTG CCC GGA GTG AGC GAG CAC CTC AAG CTG AAC GGA AAA GTC CTG GCG  
 604  
 Leu Pro Gly Val Ser Glu His Leu Lys Leu Asn Gly Lys Val Leu Ala  
 140 145 150

GCC ATG TAC CAG GGC ACC ATC AAA ACC TGG GAC GAC CCG CAG ATC GCT  
 652  
 Ala Met Tyr Gln Gly Thr Ile Lys Thr Trp Asp Asp Pro Gln Ile Ala  
 155 160 165

GCG CTC AAC CCC GGC GTG AAC CTG CCC GGC ACC GCG GTA GTT CCG CTG  
 700  
 Ala Leu Asn Pro Gly Val Asn Leu Pro Gly Thr Ala Val Val Pro Leu  
 170 175 180

CAC CGC TCC GAC GGG TCC GGT GAC ACC TTC TTG TTC ACC CAG TAC CTG  
 748  
 His Arg Ser Asp Gly Ser Gly Asp Thr Phe Leu Phe Thr Gln Tyr Leu  
 185 190 195

TCC AAG CAA GAT CCC GAG GGC TGG GGC AAG TCG CCC GGC TTC GGC ACC  
 796  
 Ser Lys Gln Asp Pro Glu Gly Trp Gly Lys Ser Pro Gly Phe Gly Thr  
 200 205 210 215

ACC GTC GAC TTC CCG GCG GTG CCG GGT GCG CTG GGT GAG AAC GGC AAC  
 844  
 Thr Val Asp Phe Pro Ala Val Pro Gly Ala Leu Gly Glu Asn Gly Asn  
 220 225 230

GGC GGC ATG GTG ACC GGT TGC GCC GAG ACA CCG GGC TGC GTG GCC TAT  
 892  
 Gly Gly Met Val Thr Gly Cys Ala Glu Thr Pro Gly Cys Val Ala Tyr  
 235 240 245

Fig. 3 B

6 / 47

ATC GGC ATC AGC TTC CTC GAC CAG GCC AGT CAA CGG GGA CTC GGC GAG  
 940  
 Ile Gly Ile Ser Phe Leu Asp Gln Ala Ser Gln Arg Gly Leu Gly Glu  
 250 255 260

GCC CAA CTA GGC AAT AGC TCT GGC AAT TTC TTG TTG CCC GAC GCG CAA  
 988  
 Ala Gln Leu Gly Asn Ser Ser Gly Asn Phe Leu Leu Pro Asp Ala Gln  
 265 270 275

AGC ATT CAG GCC GCG GCG GCT GGC TTC GCA TCG AAA ACC CCG GCG AAC  
 1036  
 Ser Ile Gln Ala Ala Ala Ala Gly Phe Ala Ser Lys Thr Pro Ala Asn  
 280 285 290 295

CAG GCG ATT TCG ATG ATC GAC GGG CCC GCC CCG GAC GGC TAC CCG ATC  
 1084  
 Gln Ala Ile Ser Met Ile Asp Gly Pro Ala Pro Asp Gly Tyr Pro Ile  
 300 305 310

ATC AAC TAC GAG TAC GCC ATC GTC AAC AAC CGG CAA AAG GAC GCC GCC  
 1132  
 Ile Asn Tyr Glu Tyr Ala Ile Val Asn Asn Arg Gln Lys Asp Ala Ala  
 315 320 325

ACC GCG CAG ACC TTG CAG GCA TTT CTG CAC TGG GCG ATC ACC GAC GGC  
 1180  
 Thr Ala Gln Thr Leu Gln Ala Phe Leu His Trp Ala Ile Thr Asp Gly  
 330 335 340

AAC AAG GCC TCG TTC CTC GAC CAG GTT CAT TTC CAG CCG CTG CCG CCC  
 1228  
 Asn Lys Ala Ser Phe Leu Asp Gln Val His Phe Gln Pro Leu Pro Pro  
 345 350 355

GCG GTG GTG AAG TTG TCT GAC GCG TTG ATC GCG ACG ATT TCC AGC  
 1273  
 Ala Val Val Lys Leu Ser Asp Ala Leu Ile Ala Thr Ile Ser Ser  
 360 365 370

TAGCCTCGTT GACCACCACG CGACAGCAAC CTCCGTCGGG CCATCGGGCT GCTTTGCGGA  
 1333

GCATGCTGGC CCGTGCCGGT GAAGTCGGCC GCGCTGGCCC GGCCATCCGG TGGTTGGGTG  
 1393

Fig. 3c

GGATAGGTGC GGTGATCCCG CTGCTTGCGC TGGTCTTGGT GCTGGTGGTG CTGGTCATCG  
1453

AGGCGATGGG TGC GATCAGG CTCAACGGGT TGCATTTCTT CACCGCCACC GAATGGAATC  
1513

CAGGCAACAC CTACGGCGAA ACCGTTGTCA CCGACGCGTC GCCCATCCGG TCGGCGCCTA  
1573

CTACGGGGCG TTGCCGCTGA TCGTCGGGAC GCTGGCGACC TCGGCAATCG CCCTGATCAT  
1633

CGCGGTGCCG GTCTCTGTAG GAGCGGCGCT GGTGATCGTG GAACGGCTGC CGAAACGGTT  
1693

GGCCGAGGCT GTGGGAATAG TCCTGGAATT GCTCGCCGGA ATCCCCAGCG TGGTCGTCGG  
1753

TTTGTGGGGG GCAATGACGT TCGGGCCGTT CATCGCTCAT CACATCGCTC CGGTGATCGC  
1813

TCACAACGCT CCCGATGTGC CGGTGCTGAA CTA CT TGCGC GCGACCCGG GCAACGGGGA  
1873

GGGCATGTTG GTGTCCGGTC TGGTGTGGC GGTGATGGTC GTTCCCATT TCGCCACCAC  
1933

CACTCATGAC CTGTTCCGGC AGGTGCCGGT GTTGCCCCGG GAGGGCGCGA TCGGGAATTC  
1993

Fig. 3D

GGTCTTGACC ACCACCTGGG TGTCTGAAGTC GGTGCCCCGA TTGAAGTCCA GGTACTCGTG	60
GGTGGGGCGG GCGAAACAAT AGCGACAAGC ATGCGAGCAG CCGCGGTAGC CGTTGACGGT	120
GTAGCGAAAC GGCAACGCGG CCGCGTTGGG CACCTTGTTT AGCGCTGATT TGCACAACAC	180
CTCGTGGAAG GTGATGCCGT CGAATTGTGG CGCGCGAACG CTGCGGACCA GGCCGATCCG	240
CTGCAACCCG GCAGCGCCCG TCGTCAACGG GCATCCCGTT CACCGCGACG GCTTGCCGGG	300
CCCAACGCAT ACCATTATTC GAACAACCGT TCTATACTTT GTCAACGCTG GCCGCTACCG	360
AGCGCCGCAC AGGATGTGAT ATGCCATCTC TGCCCGCACA GACAGGAGCC AGGCCTTATG	420
ACAGCATTCG GCGTCGAGCC CTACGGGCAG CCGAAGTACC TAGAAATCGC CGGGAAGCGC	480
ATGGCGTATA TCGACGAAGG CAAGGGTGAC GCCATCGTCT TTCAGCACGG CAACCCACG	540
TCGTCTTACT TGTGGCGCAA CATCATGCCG CACTTGGAAG GGCTGGGCCG GCTGGTGCC	600
TGCGATCTGA TCGGGATGGG CGCGTCGGAC AAGCTCAGCC CATCGGGACC CGACCGCTAT	660
AGCTATGGCG AGCAACGAGA CTTTTGTTC GCGCTCTGGG ATGCGCTCGA CCTCGGCGAC	720
CACGTGGTAC TGGTGCTGCA CGACTGGGGC TCGGCGCTCG GCTTCGACTG GGCTAACCAG	780
CATCGCGACC GAGTGCAGGG GATCGCGTTC ATGGAAGCGA TCGTCACCCC GATGACGTGG	840
GCGGACTGGC CGCCGGCCGT GCGGGGTGTG TTCCAGGGTT TCCGATCGCC TCAAGGCGAG	900
CCAATGGCGT TGGAGCACAA CATCTTTGTC GAACGGGTGC TGCCCGGGGC GATCCTGCGA	960
CAGCTCAGCG ACGAGGAAAT GAACCACTAT CGGCGGCCAT TCGTGAACGG CGGCGAGGAC	1020
CGTCGCCCCA CGTTGTCTGT GCCACGAAAC CTTCCAATCG ACGGTGAGCC CGCCGAGGTC	1080
GTCGCGTTGG TCAACGAGTA CCGGAGCTGG CTCGAGGAAA CCGACATGCC GAAACTGTTC	1140
ATCAACGCCG AGCCCGGCGC GATCATCACC GGCCGCATCC GTGACTATGT CAGGAGCTGG	1200
CCCAACCAGA CCGAAATCAC AGTGCCCGGC GTGCATTTTC TTCAGGAGGA CAGCGATGGC	1260

Fig 4A

9 / 47

GTCGTATCGT	GGGCGGGCGC	TCGGCAGCAT	CGGCGACCTG	GGAGCGCTCT	CATTTACGA	1320
GACCAAGAAT	GTGATTTCG	GCGAAGGCGG	CGCCCTGCTT	GTCAACTCAT	AAGACTTCCT	1380
GCTCCGGGCA	GAGATTCTCA	GGGAAAAGGG	CACCAATCGC	AGCCGCTTCC	TTCGCAACGA	1440
GGTCGACAAA	TATACGTGGC	AGGACAAAGG	TCTTCCTATT	TGCCCAGCGA	ATTAGTCGCT	1500
GCCTTTCTAT	GGGCTCAGTT	CGAGGAAGCC	GAGCGGATCA	CGCGTATCCG	ATTGGACCTA	1560
TGGAACCGGT	ATCATGAAAG	CTTCGAATCA	TTGGAACAGC	GGGGGCTCCT	GCGCCGTCCG	1620
ATCATCCAC	AGGGCTGCTC	TCACAACGCC	CACATGTACT	ACGTGTTACT	AGCGCCCAGC	1680
GCCGATCGGG	AGGAGGTGCT	GGCGCGTCTG	ACGAGCGAAG	GTATAGGCGC	GGTCTTTCAT	1740
TACGTGCCGC	TTCACGATTC	GCCGGCCGGG	CGTCGCT			1777

Fig. 4B

10 / 47

## TbH-9: protein sequence

```

Val Ala Trp Met Ser Val Thr Ala Gly Gln Ala Glu Leu Thr Ala Ala
1           5           10           15

Gln Val Arg Val Ala Ala Ala Ala Tyr Glu Thr Ala Tyr Gly Leu Thr
20           25           30

Val Pro Pro Pro Val Ile Ala Glu Asn Arg Ala Glu Leu Met Ile Leu
35           40           45

Ile Ala Thr Asn Leu Leu Gly Gln Asn Thr Pro Ala Ile Ala Val Asn
50           55           60

Glu Ala Glu Tyr Gly Glu Met Trp Ala Gln Asp Ala Ala Ala Met Phe
65           70           75           80

Gly Tyr Ala Ala Ala Thr Ala Thr Ala Thr Ala Thr Leu Leu Pro Phe
85           90           95

Glu Glu Ala Pro Glu Met Thr Ser Ala Gly Gly Leu Leu Glu Gln Ala
100          105          110

Ala Ala Val Glu Glu Ala Ser Asp Thr Ala Ala Ala Asn Gln Leu Met
115          120          125

Asn Asn Val Pro Gln Ala Leu Lys Gln Leu Ala Gln Pro Thr Gln Gly
130          135          140

Thr Thr Pro Ser Ser Lys Leu Gly Gly Leu Trp Lys Thr Val Ser Pro
145          150          155          160

His Arg Ser Pro Ile Ser Asn Met Val Ser Met Ala Asn Asn His Met
165          170          175

Ser Met Thr Asn Ser Gly Val Ser Met Thr Asn Thr Leu Ser Ser Met
180          185          190

Leu Lys Gly Phe Ala Pro Ala Ala Ala Ala Gln Ala Val Gln Thr Ala
195          200          205

Ala Gln Asn Gly Val Arg Ala Met Ser Ser Leu Gly Ser Ser Leu Gly
210          215          220

```

Fig. 4c

11 / 47

Ser Ser Gly Leu Gly Gly Gly Val Ala Ala Asn Leu Gly Arg Ala Ala  
 225 230 235 240

Ser Val Arg Tyr Gly His Arg Asp Gly Gly Lys Tyr Ala Xaa Ser Gly  
 245 250 255

Arg Arg Asn Gly Gly Pro Ala  
 260

Tb38-1: protein sequence

Thr Asp Ala Ala Thr Leu Ala Gln Glu Ala Gly Asn Phe Glu Arg Ile  
 1 5 10 15

Ser Gly Asp Leu Lys Thr Gln Ile Asp Gln Val Glu Ser Thr Ala Gly  
 20 25 30

Ser Leu Gln Gly Gln Trp Arg Gly Ala Ala Gly Thr Ala Ala Gln Ala  
 35 40 45

Ala Val Val Arg Phe Gln Glu Ala Ala Asn Lys Gln Lys Gln Glu Leu  
 50 55 60

Asp Glu Ile Ser Thr Asn Ile Arg Gln Ala Gly Val Gln Tyr Ser Arg  
 65 70 75 80

Ala Asp Glu Glu Gln Gln Gln Ala Leu Ser Ser Gln Met Gly Phe  
 85 90 95

Fig. 4D



12 / 47

TGGCGAATGG GACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG	60
CAGCGTGACC GCTACACTTG CCAGCGCCCT AGCGCCCGCT CCTTTCGCTT TCTTCCCTTC	120
CTTTCTCGCC ACGTTCGCCG GCTTTCCTCCG TCAAGCTCTA AATCGGGGGC TCCCTTTAGG	180
GTTCCGATTT AGTGCTTTAC GGCACCTCGA CCCCAGAAAA CTTGATTAGG GTGATGGTTC	240
ACGTAGTGGG CCATCGCCCT GATAGACGGT TTTTCGCCCT TTGACGTTGG AGTCCACGTT	300
CTTTAATAGT GGACTCTTGT TCCAACTGG AACAACACTC AACCCTATCT CGGTCTATTC	360
TTTTGATTTA TAAGGGATTT TGCCGATTTC GGCCTATTGG TTAAAAAATG AGCTGATTTA	420
ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGTTT ACAATTTTCA GTGGCACTTT	480
TCGGGGAAAT GTGCGCGGAA CCCCTATTTC TTTATTTTTC TAAATACATT CAAATATGTA	540
TCCGCTCATG AATTAATTCT TAGAAAACT CATCGAGCAT CAAATGAAAC TGCAATTTAT	600
TCATATCAGG ATTATCAATA CCATATTTT GAAAAAGCCG TTTCTGTAAT GAAGGAGAAA	660
ACTCACCGAG GCAGTTCCAT AGGATGGCAA GATCCTGGTA TCGGTCTGCG ATTCCGACTC	720
GTCCAACATC AATACAACCT ATTAATTTCC CCTCGTCAAA AATAAGGTTA TCAAGTGAGA	780
AATCACCATG AGTGACGACT GAATCCGGTG AGAATGGCAA AAGTTTATGC ATTTCTTTCC	840
AGACTTGTTT AACAGGCCAG CCATTACGCT CGTCATCAAA ATCACTCGCA TCAACCAAAC	900
CGTTATTCAT TCGTGATTGC GCCTGAGCGA GACGAAATAC GCGATCGCTG TTAAAAGGAC	960
AATTACAAAC AGGAATCGAA TGCAACCGGC GCAGGAACAC TGCCAGCGCA TCAACAATAT	1020
TTTCACCTGA ATCAGGATAT TCTTCTAATA CCTGGAATGC TGTTTTCCCG GGGATCGCAG	1080
TGGTGAGTAA CCATGCATCA TCAGGAGTAC GGATAAAATG CTTGATGGTC GGAAGAGGCA	1140
TAAATCCGT CAGCCAGTTT AGTCTGACCA TCTCATCTGT AACATCATTG GCAACGCTAC	1200
CTTGCCATG TTTAGAAAC AACTCTGGCG CATCGGGCTT CCCATACAAT CGATAGATTG	1260

Fig. 5A

TCGCACCTGA	TTGCCCCGACA	TTATCGCGAG	CCCATTATA	CCCATATAAA	TCAGCATCCA	1320
TGTTGGAATT	TAATCGCGGC	CTAGAGCAAG	ACGTTTCCCG	TTGAATATGG	CTCATAACAC	1380
CCCTTGATAT	ACTGTTTATG	TAAGCAGACA	GTTTATTGT	TCATGACCAA	AATCCCTTAA	1440
CGTGAGTTTT	CGTTCCACTG	AGCGTCAGAC	CCCGTAGAAA	AGATCAAAGG	ATCTTCTTGA	1500
GATCCTTTTT	TTCTGCGCGT	AATCTGCTGC	TTGCAAACAA	AAAAACCACC	GCTACCAGCG	1560
GTGGTTTGTT	TGCCGGATCA	AGAGCTACCA	ACTCTTTTTC	CGAAGGTAAC	TGGCTTCAGC	1620
AGAGCGCAGA	TACCAAATAC	TGTCCTTCTA	GTGTAGCCGT	AGTTAGGCCA	CCACTTCAAG	1680
AATCTGTAG	CACCGCCTAC	ATACCTCGCT	CTGCTAATCC	TGTTACCAGT	GGCTGCTGCC	1740
AGTGCGGATA	AGTCGTGTCT	TACCGGGTTG	GACTCAAGAC	GATAGTTACC	GGATAAGGCG	1800
CAGCGGTCGG	GCTGAACGGG	GGGTTGCTGC	ACACAGCCCA	GCTTGGAGCG	AACGACCTAC	1860
ACCGAACTGA	GATACCTACA	GCGTGAGCTA	TGAGAAAGCG	CCACGCTTCC	CGAAGGGAGA	1920
AAGGCGGACA	GGTATCCGGT	AAGCGGCAGG	GTGGAACAG	GAGAGCGCAC	GAGGGAGCTT	1980
CCAGGGGGAA	ACGCCTGGTA	TCTTTATAGT	CCTGTCGGGT	TTGCCACCT	CTGACTTGAG	2040
CGTCGATTTT	TGTGATGCTC	GTCAGGGGGG	CGGAGCCTAT	GGAAAAACGC	CAGCAACGCG	2100
GCCTTTTTTAC	GGTTCCTGGC	CTTTTGCTGG	CCTTTTGCTC	ACATGTTCTT	TCCTGCGTTA	2160
TCCCCTGATT	CTGTGGATAA	CCGTATTACC	GCCTTTGAGT	GAGCTGATAC	CGCTCGCCGC	2220
AGCCGAACGA	CCGAGCGCAG	CGAGTCAGTG	AGCGAGGAAG	CGGAAGAGCG	CCTGATGCGG	2280
TATTTTCTCC	TTACGCATCT	GTGCGGTATT	TCACACCGCA	TATATGGTGC	ACTCTCAGTA	2340
CAATCTGCTC	TGATGCCGCA	TAGTTAAGCC	AGTATACACT	CCGCTATCGC	TACGTGACTG	2400
GGTCATGGCT	GCGCCCCGAC	ACCCGCCAAC	ACCCGCTGAC	GCGCCCTGAC	GGGCTTGTCT	2460
GCTCCCGGCA	TCCGCTTACA	GACAAGCTGT	GACCGTCTCC	GGGAGCTGCA	TGTGTCAGAG	2520
GTTTTACCCG	TCATCACCAG	AACGCGCGAG	GCAGCTGCGG	TAAAGCTCAT	CAGCGTGGTC	2580
GTGAAGCGAT	TCACAGATGT	CTGCCTGTTT	ATCCGCGTCC	AGCTCGTTGA	GTTTCTCCAG	2640
AAGCGTTAAT	GTCTGGCTTC	TGATAAAGCG	GGCCATGTTA	AGGGCGGTTT	TTTCTGTTT	2700

GGTCACTGAT GCCTCCGTGT AAGGGGGATT TCTGTTTCATG GGGGTAATGA TACCGATGAA	2760
ACGAGAGAGG ATGCTCACGA TACGGGTTAC TGATGATGAA CATGCCCGGT TACTGGAACG	2820
TTGTGAGGGT AAACAACTGG CGGTATGGAT GCGGCGGGAC CAGAGAAAAA TCACTCAGGG	2880
TCAATGCCAG CGCTTCGTTA ATACAGATGT AGGTGTTCCA CAGGGTAGCC AGCAGCATCC	2940
TGCGATGCAG ATCCGGAACA TAATGGTGCA GGGCGCTGAC TTCCGCGTTT CCAGACTTTA	3000
CGAAACACGG AAACCGAAGA CCATTCATGT TGTGCTCAG GTCGCAGACG TTTTGACGCA	3060
GCAATCGCTT CACGTTTCGCT CGCGTATCGG TGATTCATTC TGCTAACCAG TAAGGCAACC	3120
CCGCCAGCCT AGCCGGGTCC TCAACGACAG GAGCACGATC ATGCGCACCC GTGGGGCCGC	3180
CATGCCGGCG ATAATGGCCT GCTTCTCGCC GAAACGTTTG GTGGCGGGAC CAGTGACGAA	3240
GGCTTGAGCG AGGGCGTGCA AGATTCCGAA TACCGCAAGC GACAGGCCGA TCATCGTCGC	3300
GCTCCAGCGA AAGCGGTCCT CGCCGAAAAT GACCCAGAGC GCTGCCGGCA CCTGTCCTAC	3360
GAGTTGCATG ATAAAGAAGA CAGTCATAAG TGCGGCGACG ATAGTCATGC CCCGCGCCCA	3420
CCGGAAGGAG CTGACTGGGT TGAAGGCTCT CAAGGGCATC GGTGAGATC CCGGTGCCTA	3480
ATGAGTGAGC TAACTTACAT TAATTGCGTT GCGCTCACTG CCCGCTTTCC AGTCGGGAAA	3540
CCTGTCGTGC CAGCTGCATT AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT	3600
TGGGCGCCAG GGTGGTTTTT CTTTTACCA GTGAGACGGG CAACAGCTGA TTGCCCTTCA	3660
CCGCCTGGCC CTGAGAGAGT TGCAGCAAGC GGTCCACGCT GGTGTGCCCC AGCAGGCGAA	3720
AATCCTGTTT GATGGTGGTT AACGGCGGGA TATAACATGA GCTGTCTTCG GTATCGTCGT	3780
ATCCCACTAC CGAGATATCC GCACCAACGC GCAGCCCGGA CTCGGTAATG GCGCGCATTG	3840
CGCCAGCGC CATCTGATCG TTGGCAACCA GCATCGCAGT GGGAACGATG CCCTCATTC	3900
GCATTTGCAT GGTGTGTTGA AAACCGGACA TGGCACTCCA GTCGCCTTCC CGTTCCGCTA	3960
TCGGCTGAAT TTGATTGCCA GTGAGATATT TATGCCAGCC AGCCAGACGC AGACGCGCCG	4020
AGACAGAACT TAATGGGCCC GCTAACAGCG CGATTTGCTG GTGACCCAAT GCGACCAGAT	4080
GCTCCACGCC CAGTCGCGTA CCGTCTTCAT GGGAGAAAAT AATACTGTTG ATGGGTGTCT	4140

GGTCAGAGAC ATCAAGAAAT AACGCCGGAA CATTAGTGCA GGCAGCTTCC ACAGCAATGG	4200
CATCCTGGTC ATCCAGCGGA TAGTTAATGA TCAGCCCCT GACGCGTTGC GCGAGAAGAT	4260
TGTGCACCGC CGCTTTACAG GCTTCGACGC CGCTTCGTTT TACCATCGAC ACCACCACGC	4320
TGGCACCCAG TTGATCGGCG CGAGATTTAA TCGCCCGGAC AATTTGCGAC GGC GCGTGCA	4380
GGGCCAGACT GGAGGTGGCA ACGCCAATCA GCAACGACTG TTTGCCCGCC AGTTGTTGTG	4440
CCACGCGGTT GGGAATGTAA TTCAGCTCCG CCATCGCCGC TTCCACTTTT TCCCGCGTTT	4500
TCGCAGAAAC GTGGCTGGCC TGGTTCACCA CGCGGGAAAC GGTCTGATAA GAGACACCGG	4560
CATACTCTGC GACATCGTAT AACGTTACTG GTTTCACATT CACCACCCTG AATTGACTCT	4620
CTTCCGGGCG CTATCATGCC ATACCGCGAA AGGTTTTGCG CCATTCGATG GTGTCCGGGA	4680
TCTCGACGCT CTCCCTTATG CGACTCCTGC ATTAGGAAGC AGCCCAGTAG TAGGTTGAGG	4740
CCGTTGAGCA CCGCCGCCGC AAGGAATGGT GCATGCAAGG AGATGGCGCC CAACAGTCCC	4800
CCGGCCACGG GGCCTGCCAC CATACCCACG CCGAAACAAG CGTCATGAG CCCGAAGTGG	4860
CGAGCCCGAT CTTCCCCATC GGTGATGTCG GCGATATAGG CGCCAGCAAC CGCACCTGTG	4920
GCGCCGGTGA TGCCGGCCAC GATGCGTCCG GCGTAGAGGA TCGAGATCTC GATCCCGCGA	4980
AATTAATACG ACTCACTATA GGGGAATTGT GAGCGGATAA CAATTCCCCT CTAGAAATAA	5040
TTTTGTTTAA CTTTAAGAAG GAGATATACA TATGGGCCAT CATCATCATC ATCACGTGAT	5100
CGACATCATC GGGACCAGCC CCACATCCTG GGAACAGGCG GCGGCGGAGG CGGTCCAGCG	5160
GGCGCGGGAT AGCGTCGATG ACATCCGCGT CGCTCGGGTC ATTGAGCAGG ACATGGCCGT	5220
GGACAGCGCC GGCAAGATCA CCTACCGCAT CAAGCTCGAA GTGTCGTTCA AGATGAGGCC	5280
GGCGCAACCG AGGGGCTCGA AACCACCGAG CGGTTGCGCT GAAACGGGCG CCGGCGCCGG	5340
TACTGTCGCG ACTACCCCCG CGTCGTCGCC GGTGACGTTG GCGGAGACCG GTAGCACGCT	5400
GCTCTACCCG CTGTTCAACC TGTGGGGTCC GGCCTTTCAC GAGAGGTATC CGAACGTCAC	5460
GATCACCGCT CAGGGCACCG GTTCTGGTGC CGGGATCGCG CAGGCCGCCG CCGGGACGGT	5520
CAACATTGGG GCCTCCGACG CCTATCTGTC GGAAGGTGAT ATGCCCGCGC ACAAGGGGCT	5580

Fig. 5D

GATGAACATC GCGCTAGCCA TCTCCGCTCA GCAGGTCAAC TACAACCTGC CCGGAGTGAG	5640
CGAGCACCTC AAGCTGAACG GAAAAGTCCT GCGGGCCATG TACCAGGGCA CCATCAAAAC	5700
CTGGGACGAC CCGCAGATCG CTGCGCTCAA CCCC GGCGTG AACCTGCCCC GCACCGCGGT	5760
AGTTCCGCTG CACCGCTCCG ACGGGTCCGG TGACACCTTC TTGTTCAACC AGTACCTGTC	5820
CAAGCAAGAT CCCGAGGGCT GGGGCAAGTC GCGCGCTTC GGCACCACCG TCGACTTCCC	5880
GGCGGTGCCG GGTGCGCTGG GTGAGAACGG CAACGGCGGC ATGGTGACCG GTTGCGCCGA	5940
GACACCGGGC TCGTGGCCT ATATCGGCAT CAGCTTCCTC GACCAGGCCA GTCAACGGGG	6000
ACTCGGCGAG GCCCAACTAG GCAATAGCTC TGGCAATTC TTGTTGCCCC ACGCGCAAAG	6060
CATTCAGGCC GCGGCGGCTG GCTTCGCATC GAAAACCCCG GCGAACCAGG CGATTTGAT	6120
GATCGACGGG CCCGCCCCGG ACGGCTACCC GATCATCAAC TACGAGTACG CCATCGTCAA	6180
CAACCGGCAA AAGGACGCCG CCACCGCGCA GACCTTGCGG GCATTTCTGC ACTGGGCGAT	6240
CACCGACGGC AACAAGGCCT CGTTCCTCGA CCAGGTTTAT TTCCAGCCGC TGCCGCCCGC	6300
GGTGGTGAAG TTGTCTGACG CGTTGATCGC GACGATTTCC AGCGCTGAGA TGAAGACCGA	6360
TGCCGCTACC CTCGCGCAGG AGGCAGGTAA TTTCGAGCGG ATCTCCGGCG ACCTGAAAAC	6420
CCAGATCGAC CAGGTGGAGT CGACGGCAGG TTCGTTGCAG GGCCAGTGGC GCGGCGCGGC	6480
GGGGACGGCC GCCCAGGCCG CGGTGGTGCG CTTCCAAGAA GCAGCCAATA AGCAGAAGCA	6540
GGAACCTCGAC GAGATCTCGA CGAATATTCG TCAGGCCGGC GTCCAATACT CGAGGGCCGA	6600
CGAGGAGCAG CAGCAGGCGC TGTCCTCGCA AATGGGCTTT GTGCCCACAA CGGCCGCCTC	6660
GCCGCCGTCG ACCGCTGCAG CGCCACCCGC ACCGGCGACA CCTGTTGCCC CCCCACCACC	6720
GGCCGCCGCC AACACGCCGA ATGCCCAGCC GGGCGATCCC AACGCAGCAC CTCCGCCGGC	6780
CGACCCGAAC GCACCGCCGC CACCTGTCAT TGCCCCAAAC GCACCCCAAC CTGTCCGGAT	6840
CGACAACCCG GTTGGAGGAT TCAGCTTCGC GCTGCCTGCT GGCTGGGTGG AGTCTGACGC	6900
CGCCCACTTC GACTACGGTT CAGCACTCCT CAGCAAAACC ACCGGGGACC CGCCATTTC	6960
CGGACAGCCG CCGCCGGTGG CCAATGACAC CCGTATCGTG CTCGGCCGGC TAGACCAAAA	7020

Fig. 5 E

17 / 47

GCTTTACGCC AGCGCCGAAG CCACCGACTC CAAGGCCGCG GCCCGGTTGG GCTCGGACAT	7080
GGGTGAGTTC TATATGCCCT ACCCGGGCAC CCGGATCAAC CAGGAAACCG TCTCGCTTGA	7140
CGCCAACGGG GTGTCTGGAA GCGCGTCGTA TTACGAAGTC AAGTTCAGCG ATCCGAGTAA	7200
GCCGAACGGC CAGATCTGGA CGGGCGTAAT CGGCTCGCCC GCGGCGAACG CACCGGACGC	7260
CGGGCCCCCT CAGCGCTGGT TTGTGGTATG GCTCGGGACC GCCAACAACC CGGTGGACAA	7320
GGGCGCGGCC AAGGCGCTGG CCGAATCGAT CCGGCCTTTG GTCGCCCCGC CGCCGGCGCC	7380
GGCACCGGCT CCTGCAGAGC CCGCTCCGGC GCCGGCGCCG GCCGGGGAAG TCGCTCCTAC	7440
CCCGACGACA CCGACACCGC AGCGGACCTT ACCGGCCTGA GAATTCTGCA GATATCCATC	7500
AACTGGCGG CCGCTCGAGC ACCACCACCA CCACCACTGA GATCCGGCTG CTAACAAAGC	7560
CCGAAAGGAA GCTGAGTTGG CTGCTGCCAC CGCTGAGCAA TAACTAGCAT AACCCTTGG	7620
GGCCTCTAAA CGGGTCTTGA GGGGTTTTTT GCTGAAAGGA GGAAGTATAT CCGGAT	7676

Fig. 5F

18 / 47

Met	Gly	His	His	His	His	His	His	Val	Ile	Asp	Ile	Ile	Gly	Thr	Ser	1	5	10	15
Pro	Thr	Ser	Trp	Glu	Gln	Ala	Ala	Ala	Glu	Ala	Val	Gln	Arg	Ala	Arg	20	25	30	
Asp	Ser	Val	Asp	Asp	Ile	Arg	Val	Ala	Arg	Val	Ile	Glu	Gln	Asp	Met	35	40	45	
Ala	Val	Asp	Ser	Ala	Gly	Lys	Ile	Thr	Tyr	Arg	Ile	Lys	Leu	Glu	Val	50	55	60	
Ser	Phe	Lys	Met	Arg	Pro	Ala	Gln	Pro	Arg	Gly	Ser	Lys	Pro	Pro	Ser	65	70	75	80
Gly	Ser	Pro	Glu	Thr	Gly	Ala	Gly	Ala	Gly	Thr	Val	Ala	Thr	Thr	Pro	85	90	95	
Ala	Ser	Ser	Pro	Val	Thr	Leu	Ala	Glu	Thr	Gly	Ser	Thr	Leu	Leu	Tyr	100	105	110	
Pro	Leu	Phe	Asn	Leu	Trp	Gly	Pro	Ala	Phe	His	Glu	Arg	Tyr	Pro	Asn	115	120	125	
Val	Thr	Ile	Thr	Ala	Gln	Gly	Thr	Gly	Ser	Gly	Ala	Gly	Ile	Ala	Gln	130	135	140	
Ala	Ala	Ala	Gly	Thr	Val	Asn	Ile	Gly	Ala	Ser	Asp	Ala	Tyr	Leu	Ser	145	150	155	160
Glu	Gly	Asp	Met	Ala	Ala	His	Lys	Gly	Leu	Met	Asn	Ile	Ala	Leu	Ala	165	170	175	
Ile	Ser	Ala	Gln	Gln	Val	Asn	Tyr	Asn	Leu	Pro	Gly	Val	Ser	Glu	His	180	185	190	
Leu	Lys	Leu	Asn	Gly	Lys	Val	Leu	Ala	Ala	Met	Tyr	Gln	Gly	Thr	Ile	195	200	205	
Lys	Thr	Trp	Asp	Asp	Pro	Gln	Ile	Ala	Ala	Leu	Asn	Pro	Gly	Val	Asn	210	215	220	

Fig. 5G

19 / 47

Leu	Pro	Gly	Thr	Ala	Val	Val	Pro	Leu	His	Arg	Ser	Asp	Gly	Ser	Gly	225	230	235	240
Asp	Thr	Phe	Leu	Phe	Thr	Gln	Tyr	Leu	Ser	Lys	Gln	Asp	Pro	Glu	Gly	245	250	255	
Trp	Gly	Lys	Ser	Pro	Gly	Phe	Gly	Thr	Thr	Val	Asp	Phe	Pro	Ala	Val	260	265	270	
Pro	Gly	Ala	Leu	Gly	Glu	Asn	Gly	Asn	Gly	Gly	Met	Val	Thr	Gly	Cys	275	280	285	
Ala	Glu	Thr	Pro	Gly	Cys	Val	Ala	Tyr	Ile	Gly	Ile	Ser	Phe	Leu	Asp	290	295	300	
Gln	Ala	Ser	Gln	Arg	Gly	Leu	Gly	Glu	Ala	Gln	Leu	Gly	Asn	Ser	Ser	305	310	315	320
Gly	Asn	Phe	Leu	Leu	Pro	Asp	Ala	Gln	Ser	Ile	Gln	Ala	Ala	Ala	Ala	325	330	335	
Gly	Phe	Ala	Ser	Lys	Thr	Pro	Ala	Asn	Gln	Ala	Ile	Ser	Met	Ile	Asp	340	345	350	
Gly	Pro	Ala	Pro	Asp	Gly	Tyr	Pro	Ile	Ile	Asn	Tyr	Glu	Tyr	Ala	Ile	355	360	365	
Val	Asn	Asn	Arg	Gln	Lys	Asp	Ala	Ala	Thr	Ala	Gln	Thr	Leu	Gln	Ala	370	375	380	
Phe	Leu	His	Trp	Ala	Ile	Thr	Asp	Gly	Asn	Lys	Ala	Ser	Phe	Leu	Asp	385	390	395	400
Gln	Val	His	Phe	Gln	Pro	Leu	Pro	Pro	Ala	Val	Val	Lys	Leu	Ser	Asp	405	410	415	
Ala	Leu	Ile	Ala	Thr	Ile	Ser	Ser	Ala	Glu	Met	Lys	Thr	Asp	Ala	Ala	420	425	430	
Thr	Leu	Ala	Gln	Glu	Ala	Gly	Asn	Phe	Glu	Arg	Ile	Ser	Gly	Asp	Leu	435	440	445	
Lys	Thr	Gln	Ile	Asp	Gln	Val	Glu	Ser	Thr	Ala	Gly	Ser	Leu	Gln	Gly	450	455	460	
Gln	Trp	Arg	Gly	Ala	Ala	Gly	Thr	Ala	Ala	Gln	Ala	Ala	Val	Val	Arg	465	470	475	480

Fig. 5 H



20 / 47

Phe	Gln	Glu	Ala	Ala	Asn	Lys	Gln	Lys	Gln	Glu	Leu	Asp	Glu	Ile	Ser	485	490	495	
Thr	Asn	Ile	Arg	Gln	Ala	Gly	Val	Gln	Tyr	Ser	Arg	Ala	Asp	Glu	Glu	500	505	510	
Gln	Gln	Gln	Ala	Leu	Ser	Ser	Gln	Met	Gly	Phe	Val	Pro	Thr	Thr	Ala	515	520	525	
Ala	Ser	Pro	Pro	Ser	Thr	Ala	Ala	Ala	Pro	Pro	Ala	Pro	Ala	Thr	Pro	530	535	540	
Val	Ala	Pro	Pro	Pro	Pro	Ala	Ala	Ala	Asn	Thr	Pro	Asn	Ala	Gln	Pro	545	550	555	560
Gly	Asp	Pro	Asn	Ala	Ala	Pro	Pro	Pro	Ala	Asp	Pro	Asn	Ala	Pro	Pro	565	570	575	
Pro	Pro	Val	Ile	Ala	Pro	Asn	Ala	Pro	Gln	Pro	Val	Arg	Ile	Asp	Asn	580	585	590	
Pro	Val	Gly	Gly	Phe	Ser	Phe	Ala	Leu	Pro	Ala	Gly	Trp	Val	Glu	Ser	595	600	605	
Asp	Ala	Ala	His	Phe	Asp	Tyr	Gly	Ser	Ala	Leu	Leu	Ser	Lys	Thr	Thr	610	615	620	
Gly	Asp	Pro	Pro	Phe	Pro	Gly	Gln	Pro	Pro	Pro	Val	Ala	Asn	Asp	Thr	625	630	635	640
Arg	Ile	Val	Leu	Gly	Arg	Leu	Asp	Gln	Lys	Leu	Tyr	Ala	Ser	Ala	Glu	645	650	655	
Ala	Thr	Asp	Ser	Lys	Ala	Ala	Ala	Arg	Leu	Gly	Ser	Asp	Met	Gly	Glu	660	665	670	
Phe	Tyr	Met	Pro	Tyr	Pro	Gly	Thr	Arg	Ile	Asn	Gln	Glu	Thr	Val	Ser	675	680	685	
Leu	Asp	Ala	Asn	Gly	Val	Ser	Gly	Ser	Ala	Ser	Tyr	Tyr	Glu	Val	Lys	690	695	700	
Phe	Ser	Asp	Pro	Ser	Lys	Pro	Asn	Gly	Gln	Ile	Trp	Thr	Gly	Val	Ile	705	710	715	720
Gly	Ser	Pro	Ala	Ala	Asn	Ala	Pro	Asp	Ala	Gly	Pro	Pro	Gln	Arg	Trp	725	730	735	

Fig. 5 I

21 / 47

Phe Val Val Trp Leu Gly Thr Ala Asn Asn Pro Val Asp Lys Gly Ala  
740 745 750

Ala Lys Ala Leu Ala Glu Ser Ile Arg Pro Leu Val Ala Pro Pro Pro  
755 760 765

Ala Pro Ala Pro Ala Pro Ala Glu Pro Ala Pro Ala Pro Ala Pro Ala  
770 775 780

Gly Glu Val Ala Pro Thr Pro Thr Thr Pro Thr Pro Gln Arg Thr Leu  
785 790 795 800

Pro Ala

Fig. 5J




Fig. 6A




Fig. 6 B

24 / 47

CATATGCATCACCATCACCATCACATGGCCACCACCTTCCCGTTGAGCGCCACCGCGGTCCTCTTCCCGAGTTTTCTGAGCTGTTCCGGGCTTCC 10  
GTATACGTAGTGGTAGTGGTAGTGTACCGGTGGTGGGAAGGCCAAGTCGGGTGGGCGCCAGGGAGAAGGGCTCAAAAGACTCGACAAGCGCCGGAAGG  
H M H H H H H M A T T L P V O R H P R S L F P E F S E L F A A F  
CGTCATTCCGCGGACTCCGGCCACCTTCGACACCGGTTGATGCGGCTGGAAGACGAGATGAAAGAGGGGCGCTACGAGGTACGCGCGGAGCTTCCCGG 20  
GCAGTAAGCGGCTGAGGCGGGTGAAGCTGTGGGCCAAGTACGCCGACCTTCTGCTCTACTTTCTCCCGCGATGCTCCATGCGCGCTCGAAGGGCC  
P S F A G L R P T F D T R L M R L E D E M K E G R Y E V R A E L P G  
GGTCGACCCCGACAAGGACGTGACATTATGGTCCGGATGGTCAGCTGACCATCAAGGCCGAGCGCACCGAGCAGAAGGACTTCGACGGTCGCTCGGAA 30  
CCAGCTGGGGCTGTTCTGCGAGCTGTAATACCAGGCGCTACCACTGACTGGTAGTTCCGGCTCGCGTGGCTCGTCTTCTGAAGCTGCCAGCGAGCCTT  
V D P D K D V D I H V R D G O L T I K A E R T E O K D F D G R S E  
TTCGCTACGGTTCCTTCGTTCCGACGGTGTGCTGCCGGTAGGTGCTGACGAGGACGACATTAAGGCCACCTACGACAAGGGCATTCTTACTGTGTCGG 40  
AAGCGCATGCCAAGGAAGCAAGCGTGCCACAGCGACGGCCATCCAGACTGCTCTGCTGTAATTCGGTGGATGCTGTTCCCGTAAGAATGACACAGCC  
F A Y G S F V R T V S L P V G A D E D D I K A T Y D K G I L T V S  
TGGCGGTTTTGGGAAGGGAAGCCAAACGAAAAGCACATTGAGATCCGGTCCACCAACAAGCTTGATCCCGTGGACGCGGTTCATTAAACACCACCTGCAATTA 50  
ACCGCCAAAGCCTTCCCTTCGGTTGGCTTTTTCGTGTAAGTCTAGGCCAGGTGGTTGTTGCAACTAGGGCACCTGCGCCAGTAATTGTGGTGGACGTTAAT  
V A V S E G K P T E K H I O I R S T N K L D P V D A V I N T T C N Y  
CGGGCAGGTAGTAGCTGCGCTCAACGCGACGGATCCGGGGGCTGCCGCACAGTTCACCGCTCACCAGTGGCGCAGTCTATTGCGCAATTTCTCGCC 60  
GCCCGTCCATCATCGACGCGAGTTGCGCTGCCAGGCCCGGCGGTGTAAGTTGCGGAGTGCCACCGGTCAGGATAAACCGGTTAAAGGAGCGG  
G O V V A A L N A T D P G A A A O F N A S P V A O S Y L R N F L A  
GCACCGCCACCTCAGCGCGCTGCCATGGCCGCGCAATTGCAAGCTGTGCCGGGGGGGACAGTACATCGGCCTTGTCGAGTCGGTTGCCGGCTCCTGCA 70  
CGTGGCGGTGGAGTCCGCGACGGTACCGGCGGTTAAGCTTCGACACGGCCCCCGCGTGTATGTAGCCGAACAGCTCAGCCAACGGCCGAGGACGT  
A P P P O R A A M A A O L O A V P G A A O Y I G L V E S V A G S C  
ACAACTATGAGCTCATGACGATTAATTACCAGTTCGGGGACGTGACGCTCATGGCGCCATGATCCGCGCTCAGGCGGCGTCCGCTTGAGGCGGAGCATCA 80  
TGTGTACTCTGAGTACTGCTAATTAATGGTCAAGCCCCGACGCTGCGAGTACCGCGGTACTAGCGCGAGTCCGCCGAGCGAACTCCGCTCGTAGT  
N N Y E L M T I N Y O F G D V D A H G A M I R A O A A S L E A E H O  
GGCCATCGTTCGTGATGTGTTGGCCGGGGTGACTTTTGGGGCGGCGCGGTTCCGGTGGCTTCCAGGAGTTCATTACCCAGTTGGGCGGTAACCTCCAG 90  
CCGGTAGCAAGCACTACACAACCGCGCCCACTGAAAACCCCGCGCGGCAAGCCACCGAAGGTCCTCAAGTAATGGGTCAACCGCGGATTGAAGGTG  
A I V R D V L A A G D F W G G A G S V A C O E F I T O L G R N F O

Fig. 7A

25 / 47

GTGATCTACGAGCAGGCCAACGCCACGGGCAGAGGTGCAGGCTGCCGGCAACAACATGGCGCAAACGACAGCGCGTCGGCTCCAGCTGGGCCACTA 10  
CACTAGATGCTCGTCCGGTTGCGGGTGCCCGTCTTCCACGTCCGACGGCGCTTGTGTACCGGTTTGGCTGTCGCGGCAGCCGAGGTGGAACCGGTGAT  
V I Y E Q A N A H G O K V O A A G N N M A O T D S A V G S S W A T  
GTATGAGCCTTTTGGATGCTCATATCCACAGTTGGTGGCTCCAGTCGGCGTTTGCCGCCAAGGCGGGCTGATGCGGCACACGATCGGTCAAGCCGA 11  
CATACTCGGAAACCTACGAGTATAGGGTGTCAACCACGGAGGGTCAGCCGCAAACGGCGTTCCGCCCGACTACGCCGTGTGCTAGCCAGTCCGGCT  
S M S L L D A H I P O L V A S O S A F A A K A G L M R H T I G O A E  
GCAGGCGCGATGTCGGCTCAGGCGTTTACCAGGGGAGTCGTCGGCGCGTTTCAGGCGCCCATGCCCGTTTGTGGCGGGCGGCCCAAAGTCAAC 12  
CGTCCGCGCTACAGCCGAGTCCGCAAAGTGGTCCCCCTCAGCAGCCGCGCAAAGTCCGGCGGGTACGGGCCAAACACCGCCGCGGGCGGTTTCAGTTG  
O A A M S A O A F H O G E S S A A F O A A H A R F V A A A A K V N  
ACCTTGTGGATGTCGCGCAGGCGAATCTGGGTGAGGCCGCCGGTACCTATGTGGCCGCGATGCTGCGGCCGCGTCGACCTATACCGGGTTCGATATC 12  
TGGAAACAACCTACAGCGCGTCCGCTTACACCCACTCCGGCGGCCATGGATACACGGCGGCTACGACGCCGCGCAGCTGGATATGGCCCAAGCTATAG  
T L L D V A O A N L G E A A G T Y V A A D A A A A S T Y T G F D I

Fig. 7B




Fig. 83



28 / 47

CATATGCATCACCATCACCATCAGATCCCGTGGACGCGGTCAATTAACACCACCTGCAATTACGGGCAGGTAGTAGCTGCGCTCAACGCCAGGATCCGG  
GTATACGTAGTGGTAGTGGTAGTGCTAGGGCACCTGCGCCAGTAATTGTGGTGGACGTTAATGCCCGTCCATCATCGACGCGAGTTGCGCTGCCCTAGGCC 1

H M H H H H H H D P V D A V I N T T C N Y G O V V A A L N A T D P

GGGCTGCCGCACAGTTCAACGCCTCACCGGTGGCGCAGTCTATTTGCGCAATTTCTCGCCGCACCGCCACCTCAGCGCGCTGCCATGGCCGCGCAATT 2  
CCCGACGCGGTGTCAAGTTGCGGAGTGGCCACCGCGTCAGGATAAACCGGTTAAAGGAGCGCGTGGCGGTGGAGTCGCGCGACGGTACCGGCGCGTTAA

G A A A O F N A S P V A O S Y L R N F L A A P P P O R A A M A A O L

GCAAGCTGTGCCGGGGGGCGGCACAGTACATCGGCCTTGTGAGTCGGTTGCCGGCTCCTGCAACAACATGAGCTCATGACGATTAATTACCAGTTCGGG 3  
CGTTCGACACGCGCCCGCGGTGTCTGTAGCGGAACAGTCAAGCAACGCGGAGGACGTTGTTGATACTCGAGTACTGCTAATTAATGGTCAAGCCC

O A V P G A A O Y I G L V E S V A G S C N N Y E L M T I N Y O F G

GACGTGACGCTCATGGCGCCATGATCCGCGCTCAGGCGCGCTCGCTTGAGGCGGAGCATCAGGCCATCGTTCGTGATGTGTTGGCCGCGGGTGACTTTT 4  
CTGCAGCTGCGAGTACCGCGGTACTAGGCGCGAGTCCGCGCGAGGCAACTCGCCTCGTAGTCCGGTAGCAAGCACTACACAACCGCGCGCCACTGAAAA

D V D A H G A M I R A O A A S L E A E H O A I V R O V L A A G D F

GGGCGCGCGCGGTTTCGGTGGCTTGCCAGGAGTTCAATACCCAGTTGGCGGTAACCTTCAGGTGATCTACGAGCAGGCCAACGCCACGGGCAGAAGGT 5  
CCCCGCGCGGCAAGCCACCGAAGGTTCTCAAGTAATGGTCAACCGGCAATTGAAGTCCACTAGATGCTCGTCCGGTTGCGGGTGCCCGTCTTCCA

W G G A G S V A C O E F I T O L G R N F O V I Y E O A N A H G O K V

GCAGGCTGCCGCAACAACATGGCGCAACCGACAGCGCGCTCGGCTCCAGCTGGGCCACTAGTATGAGCCTTTTGGATGCTCATATCCACAGTTGGTG 6  
CGTCCGACGCGGTTGTTGTACCGGTTTGCTGTGCGGCGAGCGAGGTGACCCGGTGATCATACTCGGAAAACCTACGAGTATAGGGTGTAACCCAC

O A A G N N M A O T D S A V G S S W A T S M S L L D A H I P O L V

GCCTCCAGTCGGCGTTTTCGGCCAAAGCGGGGCTGATCGGCGACACGATCGGTCAAGCCGAGCAGGCGCGGATGTGCGGCTCAGGCGTTTCACCAGGGGG 7  
CGGAGGGTCAGCCGCAACGCGGTTTCGCCCCGACTACGCGGTGTGCTAGCCAGTCCGGCTCGTCCCGGCTACAGCCGAGTCCGCAAAAGTGGTCCCCC

A S O S A F A A K A G L M R H T I G O A E O A A M S A O A F H O G

AGTCTCGCGCGGTTTCAGGCGCGCCATGCCCGTTTGTGGCGCGGCGCGCAAGTCAACACCTTGTGGATGTGCGCGAGGCGAATCTGGGTGAGGG 8  
TCAGCAGCGCGCGCAAGTCCGGCGGGTACGGGCAACACCGCGCGCGGTTTCAGTTGTGGAACAACCTACAGCGCGTCCGCTTAGACCACTCCG

E S S A A F O A A H A R F V A A A A K V N T L L D V A O A N L G E A

CCCGGTACCTATGTGGCGCGGATGCTGCGGCGCGGTGACCTATACCGGTTTCGATATCCATCACACTGGCGGCGCGTTCAGCAGATCCGGTGCTAA 9  
CGCGCATGGATACACCGCGGCTACGACGCGCGCGCAGCTGGATATGGCCAAAGTATAGGTAGTGTGACCGCGCGGAGCTCGTCTAGGCGCGAGATT

A G T Y V A A D A A A A S T Y T G F D I H H T G G R S S R S G C

Fig. 9A

---

CAAAGCCCGAAAGGAAGCTGA  
-----> 921  
GTTTCGGGCTTTCCTTCGACT  
  
O S P K G S  
----->

Fig. 9B

CATATGCATCACCATCACCATCACATGGTGGATTTTCGGGGCGTTACCACCGGAGATCAACTCCGCGAGGATGTACGCCGGCCCGGGTTCGGCCTCGCTGG 10  
GTATACGTAGTGGTAGTGGTAGTGTACCACTAAAGCCCCGCAATGGTGGCCTCTAGTTGAGGCGCTCCTACATGCCGGCCGGGCCAAGCCGGAGCGACC  
H M H H H H H H M V D F G A L P P E I N S A R M Y A C P G S A S L  
TGGCCGCGGCTCAGATGTGGGACAGCGTGGCGAGTGACCTGTTTTCGGCCGCGTCGGCGTTTCAGTCGGTGGTCTGGGGTCTGACGGTGGGGTCTGGGAT 20  
ACCGGCGCGAGTCTACACCTGTGCGACCGCTCACTGGACAAAAGCCGGCGCAGCGCGAAAGTCAGCCACCAGACCCAGACTGCCACCCAGCACCTA  
V A A A D H W D S V A S D L F S A A S A F O S V V W G L T V G ' S W I  
AGGTTCTGTCGGCGGGTCTGATGGTGGCGGCGGCTCGCCGTATGTGGCGTGGATGAGCGTCACCGCGGGGCGAGCCGAGCTGACCGCGCGCCAGGTCCGG 30  
TCCAAGCAGCGCGCCAGACTACCACCGCGCGGAGCGGCATACCGCACTCTCGCAGTGGCGCCCGCTCGGCTCGACTGGCGGGGGTCCAGGCC  
G S S A G L M V A A A S P Y V A W M S V T A G O A E L T A A O V R  
GTTGCTCGCGCGGCTACGAGACGGCGTATGGGCTGACGGTGCCCCCGCGGTGATCGCGGAGAACCGTGCTGAACGTGATGATTCTGATAGCGACCAACC 40  
CAACGACGCGCGCGGATGCTCTGCCCATACCGACTGCCACGGGGGCGGCCACTAGCGGCTCTTGGCACCACTTGACTACTAAGACTATCGCTGGTGG  
V A A A A Y E T A Y G L T V P P P V I A E N R A E L M I L I A T N  
TCTTGGGGCAAAACACCCCGGCGATCGCGGTCAACGAGGCGGAATACGGCGAGATGTGGGCCCAAGACGCCGCGCGATGTTTGGCTACGCCGCGCGGAC 50  
AGAACCCCGTTTTGTGGGGCGCTAGCGCCAGTTGCTCGGGCTTATGCCGCTCTACACCGGGTTCTGCGGCGGCGCTACAAACCGATCGCGCGCGCGT  
L L G O N T P A I A Y N E A E Y G E M W A O D A A A H F G Y A A A T  
GGCGACGGCGAGCGCGAGCTTGCTGCCGTTTCGAGGAGGCGCGGAGATGACAGCGCGGGTGGGCTCCTCGAGCAGGCGCGCGGTCGAGGAGGCTCC 60  
CCGCTGCCGCTGCCGCTGCAACGACGGCAAGCTCCTCGCGGCTCTACTGGTCGGCCCCACCGAGGAGCTCGTCCGGCGGCGCCAGCTCCTCGGAGG  
A T A T A T L L P F E E A P E M T S A G G L L E D A A A V E E A S  
GACACCGCGCGGCGAACCAGTTGATGAACAATGTGCCCCAGGCGCTGCAACAGCTGGCCCCAGCCACGAGGGCACCACGCTTCTTCCAAGCTGGGTG 70  
CTGTGGCGGCGCGCTTGGTCAACTACTTGTACACGGGTCCGCGACGTTGTGACCGGGTGGGTGCGTCCCGTGGTGGGAAGAAGTTTCAGCCAC  
D T A A A N O L M N N V P O A L O O L A O P T O G T T P S S K L G  
GCCTGTGGAAGACGGTCTCGCCGATCGGTGCGCGATCAGCAACATGGTGTGATGGCCAACAACCATGTGATGACCAACTCGGGTGTGTCGATGAC 8  
CGGACACCTTCTGCCAGAGCGCGCTAGCCAGCGCTAGTCGTTGTACCACAGTACCAGTTGTTGGTGTACAGCTACTGGTTAGGCCACACAGCTACTG  
G L W K T Y S P H R S P I S N M V S M A N N H M S M T N S G V S M T  
CAACACCTTGAGCTCGATGTTGAAGGGCTTTGCTCGCGCGCGCGCGCCAGGCCGTGCAACCGCGCGGCAAAACGGGGTCCGGGCGATGAGCTCGCTG 9  
GTTGTGGAACTCGAGCTACAACTTCCGAAACGAGGCGCGCGCGCGCGGTTCGGGACGTTTGGCGCGCGTTTGGCCCGAGGCGCGCTACTCGAGCGAC  
N T L S S M L K G F A P A A A A O A V O T A A O N G V R A M S S L

AGCAGCTCGCTGGGTTCTTCGGGTCTGGGGGTGGGGTGGCCGCCAACTTGGGTGGGGGGGCTCGGTGGGTTGGTGTGGTGGCCAGGCTGGGCGG  
CCGTGAGCGACCCAAGAAGCCAGACCCGCCACCCACCGCGGTTGAACCCAGCCCGCGAGCCAGCAAGCAACAGCCACGGCGTCCGGACCCGGC 10  
G S S L G S S G L G G G V A A N L G R A A S V G S L S V P O A W A  
GGCCAACCAGGCAGTCACCCCGGCGCGGGGCGCTGCCGTGACCAGCCTGACCAGCGCCGCGAAACAGGGCCCGGGCAGATGCTGGCGGGCTGCC  
CCCGTTGGTCCGTGAGTGGGGCCCGCGCCCGCGACGGCGACTGGTGGACTGGTGGCGGCGCTTCTCCCGGGCCCGTCTACGACCCGCCGACGG 11  
A A N O A V T P A A R A L P L T S L T S A A E R G P G O H L G G L P  
GGTGGGCAGATGGGCGCCAGGGCCGGTGGTGGGCTCAGTGGTGTGCTGGTGTTCGCGCGGACCTATGTGATGCCGATTCTCCGGCAGCCGCAAG 12  
CCACCCCGTCTACCCCGGTCCCGGCCACCCCGAGTCACCCACGACGACACAGGCGCGCTGGGATACACTACGGCGTAAGAGGCGCTGGCGGTTTC  
V G O H G A R A G G G L S G V L R V P P R P Y V M P H S P A A G K  
CTTGATCCCGTGGACGGGTCTTAACACCACCTGCAATTACGGGCAGGTAGTAGCTGCGCTCAACCGGACGGATCCGGGGGCTGCCGCACAGTTCAACG 13  
GAAGTAGGGCAGCTGCGCCAGTAATTGTGGTGGACGTTAATGCCCGTCCATCATCGACGCGAGTTGCGCTGCCCTAGGCCCGCGACGGCGTGTCAAGTTGC  
L D P V D A V I N T T C N Y G O V V A A L N A T D P G A A A O F N  
CTCACCGGTGGCGCAGTCCATTTTGGCAATTTCTCGCGCCACCGCCACCTCAGCGCGCTGCCATGGCCGCGCAATTGCAAGCTGTGCCGGGGGCGGC 14  
GGAGTGGCCACCGCGTCAGGATAAACCGGTTAAGGAGCGCGTGGCGGTGGAGTCGCGGACGGTACCGCGCGTTAACGTTGACACGGCCCCCGCGC  
A S P V A O S Y L R N F L A A P P P O R A A H A A O L O A V P G A A  
ACAGTACATCGGCCTTGTGAGTGGTTCGCCGCTCCTGCAACAATATGAGCTCATGACGATTAATTACAGTTCGGGGACGTGACGCTCATGGCGCC 15  
TGTCATGTAGCCGCAACAGCTCAGCCAACGCCGAGGACGTTGTTGATACTCGAGTACTGCTAATTAATGGTCAAGCCCCGACGTCGGAGTACCGCGG  
O Y I G L V E S V A G S C N N Y E L M T I N Y O F G D V D A H G A  
ATGATCCGCGCTCAGGCGCGCTCGCTTGGGCGGAGCATCAGGCCATCGTTCGTGATGTGTGGCCGCGGGTGAATTTGGGGCGGCGCGGTTCCGGTG 16  
TACTAGGCGCGAGTCCGCCGACGGAACCTCCGCTCGTAGTCGGTAGCAAGCACTACACAACCGCGCCCACTGAAAACCCCGCGGCGCAAGCCACC  
M I R A O A A S L E A E H O A I V R D V L A A G D F W G G A G S V  
CTTGCCAGGAGTTCATTACCCAGTTGGGCGTAACCTCCAGGTGATCTACGAGCAGGCCAACGCCACGGGCGAGAAGGTGCAGGCTGCCGGCAACAACAT 17  
GAACGGTCTCAAGTAATGGGTCAACCCGGCATTGAAGGTCCACTAGATGCTCGTCCGGTTGGGGTGCCCGTCTTCCACGTCCGACGGCGGCTGTGTGA  
A C O E F I T O L G R N F O V I Y E O A N A H G O K V O A A G N N H  
GGGCAAAACCGACAGCCCGTCCGCTCCAGCTGGGCCACTAGTAACGGCGCCAGTGTGCTGGAATTCGAGATATCCATCACACTGGCGGCGCTCGAG 18  
CCCGGTTGGCTGTGGCGGACCGAGGTCGACCCGGTGATCATTCGGCGGTCACAGGACCTTAAGAGCTCTATAGGTAGTGTACCCCGCGGCGAGCTC  
A O T D S A V G S S W A T S N C R O C A G I L O I S I L A A A R

Fig. 10B

CATATGCATCACCATCACCATCACATGGCCACCACCTTCCCGTTCAGCGCCACCCGCGGTCCCTCTTCCCGAGTCTTCTGAGCTGTTCCGGCGCTTCC 10X  
GTATACGTAGTGGTAGTGGTAGTGACCGTGGTGGGAAGGGCAAGTCGCGGTGGGCGCCAGGGAGAAGGGGTCAAAGACTCGACAAGCGCCGAAGG  
H M H H H H H H M A T T L P V O R H P R S L F P E F S E L F A A F  
CGTCATTGCGCGGACTCCGGCCACCTTCGACACCCGGTTGATGCGGTGGAAGACGAGATGAAAGAGGGGCGCTACGAGGTACGCGCGGAGCTTCCCGG 20X  
GCAGTAAGCGGCTGAGGCGGGTGAAGCTGTGGGCCAAGTACGCCGACCTTCTGCTCTACTTTCTCCCGCGATGCTCCATGCGCGCTCGAAGGGCC  
P S F A G L R P T F D T R L M R L E D E M K E G R Y E V R A E L P G  
GGTCGACCCGACAAGGACGTCGACATTATGGTCCGCGATGGTCAGCTGACCATCAAGCGCGAGCGCACCGAGCAGAAGGACTTCGACGGTCGTCGGAA 30X  
CCAGCTGGGGCTGTCTCTGCAGCTGTAATACCAGGCGCTACCAGTCGACTGGTAGTTCGCGCTCGCGTGGCTCGTCTTCTGAAGCTGCCAGCGAGCCTT  
V D P D K O V D I M V R D G O L T I K A E R T E O K D F D G R S E  
TTCGCTACGGTTCCTTCGTTCCGACGGTGTCGCTGCCGGTAGGTGCTGACGAGGACGACATTAAGGCCACCTACGACAAGGGCATTCTTACTGTGTGGG 40X  
AAGCGCATGCCAAGGAAGCAAGCGTGCCACAGCGACGCCATCCAGCTGCTCTGCTGTAATTCGGTGGATGCTGTTCCCGTAAGAATGACACAGCC  
F A Y G S F V R T V S L P V G A D E D D I K A T Y O K G I L T V S  
TGGCGTTTCGGAAGGGAAGCCAACCGAAAAGCACATTGAGATCCGGTCCACCAACAAGCTTGATCCCGTGGACGCGGTATTAAACACCACCTGCAATTA 50  
ACCGCCAAAGCCTTCCCTTCGGTTGGCTTTTCGTGTAAGTCTAGGCCAGGTGGTGTTCGAACTAGGGCACCTGCGCCAGTAATTGTGGTGGAGTTAAT  
V A V S E G K P T E K H I O I R S T N K L D P V D A V I N T T C N Y  
CGGGCAGGTAGTAGCTGCGCTCAACGCGACGGATCCGGGGGCTGCCGACAGTTCAACGCTCACCGGTGGCGAGTCTATTGCGCAATTCCTCGCC 60  
GCCCGTCCATCATCGACCGGAGTTGCGCTGCCTAGGCCCGGACGGCGTGTCAAGTTGCGGAGTGGCCACCGCGTCAGGATAAACCGTTAAAGGAGCGG  
G O V V A A L N A T D P G A A A O F N A S P V A O S Y L R N F L A  
GCACCGCCACCTCAGCGGCTGCCATGGCGCGCAATTGCAAGCTGTGCGGGGGCGGCACAGTACATCGGCCTTGTCGAGTCGGTGGCGGCTCTGCA 70  
CGTGGCGGTGGAGTCGCGCGACGGTACCGGCGGTAAAGCTTCGACACGGCCCCCGCGTGTATGTAGCCGAACAGCTCAGCCAACGGCCGAGGACGT  
A P P P O R A A M A A O L O A V P G A A O Y I G L V E S V A G S C  
ACAACTATGAGCTCATGACGATTAATTACCAGTTCGGGGACGTCGACGCTCATGGCGCCATGATCCGCGCTCAGGCGGCGTCCGTTGAGGCGGAGCATCA 80  
TGTGATACTCGAGTACTGCTAATTAATGGTCAAGCCCTGACGTCGAGTACCGCGGTACTAGGCGGAGTCCGCGCAGGCAACTCCGCTCGTAGT  
N N Y E L M T I N Y O F G D V D A H G A M I R A O A A S L E A E H O  
GGCCATCGTTCGTGATGTGTTGGCCGCGGCTGACTTTGGGGCGGCGCGGTTGCGTGGCTTGCAGGAGTTCATTACCCAGTGGCGCGTAACCTTCAG 9  
CCGGTAGCAAGCACTACACAACCGCGCCCACTGAAACCCCGCGCGCAAGGCACCGAACGCTCTCAAGTAATGGGTCAACCCCGGCTTGAAGGTC  
A I V R O V L A A G D F W G G A G S V A C O E F I T O L G R N F O

Fig 11A




Fig. 11B

CATATGCATCACCATCACCATCACATGGTGGATTTCGGGGCGTTACCAACGGAGATCAACTCCGCGAGGATGTACGCGGGCCGGGTTTCGGGCTCGCTGG 100  
GTATACGTAGTGGTAGTGGTAGTGTACCACCTAAAGCCCCGCAATGGTGGCCTCTAGTTGAGGCGCTCCTACATGCGGCGGGCCCCAAGCCGGAGCGACC  
H M H H H H H H M V D F G A L P P E I N S A R M Y A G P G S A S L  
TGGCGCGGCTCAGATGTGGGACAGCGTGGCGAGTGACCTGTTTTCGGCCGCTCGGCGTTTCAGTCGGTGGTCTGGGGTCTGACGGTGGGGTCTGGGAT 200  
ACCGGCGCGGAGTCTACACCCTGTGCGACCGCTCACTGGACAAAAGCGGCGCAGCGCAAGTCAGCCACCAGACCCAGACTGCCACCCAGCACCTA  
V A A A O M W O S V A S D L F S A A S A F O S V V W G L T V G S W I  
AGGTTGCTCGGCGGGTCTGATGGTGGCGGGCGGCTCGCCGTATGTGGCGTGGATGAGCGTCACCGCGGGGCGAGCCGAGCTGACCGCGCGCCAGGTCCGG 300  
TCCAAGCAGCGCGCCAGACTACCACCGCGCGGAGCGGCATACCGCACCTACTGCGAGTGGCGCCCGCTCGGCTCGACTGGCGGGGGTCCAGGCC  
G S S A G L M V A A A S P Y V A W M S V T A G O A E L T A A O V R  
JTTGCTGGGCGGCTACGAGACGGCGTATGGGCTGACGGTGCCCCCGCGGTGATCGCCGAGAACCCTGCTGAAGTGTGATTCTGATAGCGACCAACC 400  
CAACGACGCGCGCGGATGCTCTGCGGCATACCGGACTGCGACGGGGGGGCGCACTAGCGGCTCTTGGCAGCACTTGACTACTAAGACTATCGCTGGTGG  
V A A A A Y E T A Y G L T V P P P V I A E N R A E L M I L I A T N  
TCTTGGGCAAAACACCCCGCGATCGCGGTCAACGAGGCGAATACGGCGAGATGTGGGCCAAGACGCGCGCGATGTTTGGCTACGCGCGGGGAC 500  
AGAACCCCGTTTTGTGGGGCGGTAGCGCCAGTTGCTCGGCTTATGCGGCTCTACACCGGGTTCTGCGGCGGCGCTACAAACCGATCGCGCGCGCGT  
L L G O N T P A I A V N E A E Y G E M W A O D A A A M F G Y A A A T  
GGCGACGGCGACGGCGACGTTGCTGCGGTTTCGAGGAGGCGCGGAGATGACCAGCGGGGTGGGCTCCTCGAGCAGGCGCGCGGTCGAGGAGGCGCTCC 600  
CCGCTGCGGCTGCGGCTGCAACGACGGCAAGCTCCTCGCGGCGCTCTACTGGTGGCGGCGCCAGGAGGCTGCTCGGCGGCGCGGAGCTCCTCGGAGG  
A T A T A T L L P F E E A P E M T S A G G L L E O A A A V E E A S  
GACACCGCGCGCGCAACAGTTGATGAACAATGTGCCCCAGGCGCTGCAACAGCTGGCCGACCCACGCGGGGACCCAGCGCTTCTTCAAGCTGGGTG 700  
CTGTGGCGGCGCGCTTGGTCAACTACTTGTACACGGGGTCCGCGACGTTGTGACCGGGTGGGTGGTCCGTTGGTGGGAAGAAGTTGACCCAC  
D T A A A N O L M N N V P O A L O O L A O P T O G T T P S S K L G  
GCCTGTGGAAGACGGTCTCGCCGATCGGTCGCGGATCAGCAACATGGTGTGATGCCAACAACACATGTGATGACCAACTCGGGTGTGTCGATGAC 800  
CGGACACCTTCTGCCAGAGCGGCTAGCCAGCGGCTAGTCGTTGTACACAGCTACCGGTTGTTGGTGTACAGCTACTGGTTGAGCCACACAGCTACTG  
G L W K T V S P H R S P I S N M V S M A N N H M S M T N S G V S M T  
CAACACCTTGAGCTCGATGTTGAAGGGCTTTGCTCGGCGGCGGCGCGCCAGGCGGTGCAAAACCGGGCGCAAAACGGGGTCCGGGCGATGAGCTCGCTG 900  
GTGTGGAACCTCGAGCTACAACTTCCGAAACGAGGCGCGCGCGGGTCCGCGACGTTTGGCGCGCGGTTTTCGCCAGGCGCGCTACTCGAGCGAC  
N T L S S M L K G F A P A A A A O A V O T A A O N G V R A M S S L

Fig. 12 A

GGCAGCTCGCTGGGTTCTTCGGGCTCGGGCGGTGGGGTGGCGGCAACTTGGGTCGGGCGGCTCGGTGGTTCGTTGTCGGTGCCGAGGCGCTGGGCGG 100  
CCGTGAGCGACCAAGAAGCCAGACCCGCCACCCACCGGGGTTGAACCCAGCCCGCGGAGCCAGCCAAGCAACAGCCACGGCGTCCGACCGGGC  
G S S L G S S G L G G G V A A N L G R A A S V G S L S V P Q A W A  
CGGCCAACAGGCAGTCACCCCGGCGGCGGGCGCTGCCGTGACCAGCCTGACCAGCGCGCGGAAAGAGGGCCCGGCAGATGCTGGGCGGGCTGCC 110  
GCGGTTGGTCCGTCACTGGGGCCGCCCGCCCGGACGGCGACTGGTCGGACTGGTCGCGGCGCTTCTCCCGGGCCGCTACGACCCGCCCGACGG  
A A N Q A V T P A A R A L P L T S L T S A A E R G P G Q M L G G L P  
GGTGGGCGAGATGGGCGCCAGGGCGGTGGTGGGCTCAGTGGTGTGCTGCGTGTTCGCGCGGACCCATGTGATGCCGATTCTCCGGCAGCCGGCGAT 120  
CCACCCCGTCTACCCCGGGTCCCGGCCACCCCGAGTCACCCACGACGACCAAGGCGGCGTGGGATACACTACGGCGTAAGAGGCGCTGGCGCGTA  
V G Q M G A R A G G G L S G V L R V P P R P Y V M P H S P A A G D  
ATCGCCCCGCGGCGCTTGTGCGAGGACCGGTTCCGCGACTTCCCGCGCTGCCCTCGACCCGTCGCGATGGTCGCCCCAAGTGGGGCCACAGGTGGTCA 130  
TAGCGGGCGCGCGGAACAGCGTCTCGGCAAGCGGCTGAAGGGGCGCGACGGGGAGCTGGGCGAGCGCTACCGCGGGTTACCCCGGTTCCACCCAGT  
I A P P A L S Q D R F A D F P A L P L D P S A M V A Q V G P Q V V  
ACATCAACACCAAACTGGGCTACAACAACCGCGTGGGCGCGGGACCGGCATCGTCATCGATCCCAACGGTGTGCTGACCAACAACCGTGATCGC 140  
TGAGTTGTGGTTTACCCGATGTTGTTGCGGCACCCCGGCGCTGGCGGTAGCAGTAGCTAGGGTTGCCACAGCAGCACTGGTTGTTGGTGCACTAGCG  
N I N T K L G Y N N A V G A G T G I V I D P N G V V L T N N H V I A  
GGGCGCCACCGACATCAATGCGTTACGCGTCGGCTCCGCGCAAACTACGGCGTCGATGTGGTGGGTATGACCGCACCCAGGATGTCGGGTGCTGCGAG 150  
CCCGCGGTGGCTGTAGTTACGCAAGTCGAGCGGAGGCGGTTTGGATGCCGAGCTACCCAGCCATACTGGCGTGGGTCTACAGCGCCACGAGCTC  
G A T D I N A F S V G S G O T Y G V D V V G Y D R T Q D V A V L O  
CTGCGGGTGCCGGTGGCTGCCGTGCGCGGCGATCGGTGGCGCGCTCGCGTTGGTGAGCCCGTCGTCGCGATGGGCAACAGCGGTGGCGAGGGCGGAA 160  
GACGCGCCACGGCCACCGGACCGCAGCGCGCTAGCCACCGCGCAGCGCAACCACTCGGGCAGCAGCGCTACCCGTTGTGCGCCACCCGTCGCGCTT  
L R G A G G L P S A A I G G G V A V G E P V V A M G N S G G O G G  
CGCCCGTGCGGTGCTTGGCAGGGTGGTGGCGCTCGGCGCAAACTGTCAGGCGTCGGATTGCTGACCGGTGCCGAAGAGACATTGAACGGGTTGATCCA 170  
GCGGGGACGCGCAGGACCTCCACCCAGCGGAGCGGTTTGGCAGCTCGCAGCGCTAAGCGACTGGCCACGGCTTCTCTGTAACCTGCCCACTAGGT  
T P R A V P G R V V A L C O T V O A S D S L T G A E E T L N G L I O  
GTTGATGCCGCGATCCAGCCCGGTGATTCGGGCGGGCGCGCTCGTCAACGGCTAGGACAGGTGGTGGTATGAACAGGCGCGCTCTAGGATATC 1797  
CAAGCTACGGCGCTAGGTGGGCGCACTAAGCCCGCGCGGCGAGCAGTTGCGGATCTGTCCACCGCCATACTTGTGCGGCGCGAGGATCTATAG  
F D A A I O P C D S G C P V V H G L G O V V G H N T A A S O I

Fig. 12B






Fig. 13A

G F G D L A V C D G E K Y P D G S F W H Q W M O T W F T G P O F Y  
G V L A T L W P C A T A R E S T P P R L V L F G T S G C A K R G L P A H S T F Y  
G Y F L R L G R V C A T R A R E V P R R L V L A P V L A V L V Y R P H T S V L T

F D C V S G G E P L P G P P P P G G C G G A I P S E O P N A P . E  
S R I L V C S A R V S P S P R P A A T G V L A V G G O F S S A P O R T L S P E I  
L R L C O R R . A P P R P A A T G V L A R W G N S V R A . A . A . L E R I

F  
S

Fig. 13 B





Fig. 14A-14F



Antigens Formulated in SRAS1c




Fig. 16A-16F




Fig. 7







Fig. 18






44 / 47

Fig. 20A-20C



# D131 T Cell Proliferation



# D131 IFN $\gamma$





Fig. 21A + 21B

## D184 T Cell Proliferation



## D184 IFN $\gamma$




Fig. 22A + 22B

Fig. 23A



**D201 T Cell Proliferation****D201 IFN $\gamma$** 

Fig. 23B

Fig. 23 A + 23 B

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup>:  <b>C12N 15/31, C07K 14/35, 19/00, C12P 21/02, A61K 39/04</b></p>	<p><b>A3</b></p>	<p>(11) International Publication Number: <b>WO 99/51748</b></p> <p>(43) International Publication Date: <b>14 October 1999 (14.10.99)</b></p>
<p>(21) International Application Number: <b>PCT/US99/07717</b></p> <p>(22) International Filing Date: <b>7 April 1999 (07.04.99)</b></p> <p>(30) Priority Data:  09/056,556      7 April 1998 (07.04.98)      US  09/223,040      30 December 1998 (30.12.98)      US</p> <p>(71) Applicant: <b>CORIXA CORPORATION [US/US]; 1124 Columbia Street, Seattle, WA 98104 (US).</b></p> <p>(72) Inventors: <b>SKEIKY, Yasir, A., W.; 8327 - 25th Avenue N.W., Seattle, WA 98117 (US). ALDERSON, Mark; 1116 Grow Avenue Northwest, Bainbridge Island, WA 98116 (US). CAMPOS-NETO, Antonio; 9308 Midship Court Northeast, Bainbridge Island, WA 98110 (US).</b></p> <p>(74) Agents: <b>CORUZZI, Laura, A. et al.; Pennie &amp; Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).</b></p>		<p>(81) Designated States: <b>AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BI, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</b></p> <p><b>Published</b>  <i>With international search report.</i>  <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report:  <b>3 February 2000 (03.02.00)</b></p>

(54) Title: FUSION PROTEINS OF MYCOBACTERIUM TUBERCULOSIS ANTIGENS AND THEIR USES

**(57) Abstract**

The present invention relates to fusion proteins containing at least two *Mycobacterium tuberculosis* antigens. In particular, it relates to bi-fusion proteins which contain two individual *M. tuberculosis* antigens, tri-fusion proteins which contain three *M. tuberculosis* antigens, tetra-fusion proteins which contain four *M. tuberculosis* antigens, and penta-fusion proteins which contain five *M. tuberculosis* antigens, and methods for their use in the diagnosis, treatment and prevention of tuberculosis infection.

**Published**

*With international search report.*

*Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.*

**(88) Date of publication of the international search report:**

3 February 2000 (03.02.00)

1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/US 99/07717

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC 6 C12N15/31 C07K14/35 C07K19/00 C12P21/02 A61K39/04		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07K C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 09428 A (CORIXA CORP) 13 March 1997 (1997-03-13) abstract example 3 page 138 -page 139 claims	1-13
X	WO 97 09429 A (CORIXA CORP) 13 March 1997 (1997-03-13) abstract example 3 page 150 -page 152 claims	1-13
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
Date of the actual completion of the international search  25 November 1999		Date of mailing of the international search report  14/12/1999
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer  Panzica, G

# INTERNATIONAL SEARCH REPORT

Inter " pplication No

PCT/US 99/07717

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>PHILIPP W.J.: "An integrated map of the genome of th tubercle bacillus, Mycobacterium tuberculosis H37Rv, and comparison with Mycobacterium leprae" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 93, 1996, pages 3132-3137, XP002121036 WASHINGTON US abstract column 1, paragraph 1</p> <p style="text-align: center;">---</p>	1-13
A	<p>WO 95 01441 A (STATENS SERUMSINSTITUT ;ANDERSEN PETER (DK); ANDERSEN AASE BENGGAAR) 12 January 1995 (1995-01-12) abstract disclosure, examples</p> <p style="text-align: center;">---</p>	2-8, 10-13
X	<p>LEE B.-Y. ET AL.: "Characterization of the major membrane protein of virulent Mycobacterium tuberculosis" INFECTION AND IMMUNITY., vol. 60, 1992, pages 2066-2074, XP002086104 AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON., US ISSN: 0019-9567 the whole document</p> <p style="text-align: center;">---</p>	2-8, 10-13
A	<p>WO 95 01440 A (STATENS SERUMINSTITUT ;HASLOEV KAARE (DK); ANDERSEN AASE BENGGAARD) 12 January 1995 (1995-01-12) abstract disclosure, examples</p> <p style="text-align: center;">---</p>	1-13
A	<p>US 5 330 754 A (MUNSHI ANIL ET AL) 19 July 1994 (1994-07-19) column 5, line 1 -column 8, line 25 examples 1,2 claims</p> <p style="text-align: center;">-----</p>	1-13



# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/07717

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 9-11  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 9-11  
are directed to a method of treatment of the human/animal  
body, the search has been carried out and based on the alleged  
effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such  
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all  
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment  
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report  
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is  
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/07717

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9709428	A	13-03-1997	AU 7158696 A	27-03-1997
			BR 9610262 A	06-07-1999
			CA 2230885 A	13-03-1997
			CN 1200147 A	25-11-1998
			EP 0851927 A	08-07-1998
			HU 9900902 A	28-07-1999
			NO 980883 A	27-04-1998
			PL 325373 A	20-07-1998
WO 9709429	A	13-03-1997	AU 7158796 A	27-03-1997
			BR 9610268 A	06-07-1999
			CA 2230927 A	13-03-1997
			CN 1200146 A	25-11-1998
			EP 0850305 A	01-07-1998
WO 9501441	A	12-01-1995	AU 682879 B	23-10-1997
			AU 7068894 A	24-01-1995
			CA 2165949 A	12-01-1995
			EP 0706571 A	17-04-1996
			NZ 267984 A	22-09-1997
			US 5955077 A	21-09-1999
WO 9501440	A	12-01-1995	AU 685133 B	15-01-1998
			AU 7068694 A	24-01-1995
			EP 0749486 A	27-12-1996
US 5330754	A	19-07-1994	AU 689075 B	26-03-1998
			AU 4651193 A	24-01-1994
			EP 0649435 A	26-04-1995
			JP 7508649 T	28-09-1995
			WO 9400493 A	06-01-1994
			US 5559011 A	24-09-1996
			US 5770719 A	23-06-1998